(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 December 2002 (19.12.2002)

PCT

(10) International Publication Number
WO 02/100426 A1

(51) International Patent Classification[7]: A61K 38/17, A61P 19/02, 19/08, 19/10, A61F 2/28, C07K 14/47 // (A61K 38/17, 38:18)

(21) International Application Number: PCT/GB02/02427

(22) International Filing Date: 10 June 2002 (10.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0113606.8	8 June 2001 (08.06.2001)	GB
0200437.2	10 January 2002 (10.01.2002)	GB

(71) Applicant *(for all designated States except US)*: **SMITH & NEPHEW PLC** [GB/GB]; 15 Adam Street, London WC2N 6LA (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HARRISON, Andrew, James** [GB/GB]; 14 Pentland Drive, Huntington, York YO32 9PQ (GB). **SCULLY, Andrea, Jane** [GB/GB]; Blue Turtle Barn, Laytham, York YO42 4PR (GB). **MUSTILL, Wendy, Jane** [GB/GB]; 28 Millfield Lane, York YO10 3AF (GB). **THOMSON, Brian, Mark** [GB/GB]; 33 Burnby Lane, Pocklington, York YO42 2QE (GB).

(74) Agent: **HOBBS, John**; Group Patents & Trade Marks Department, Smith & Nephew Group Research Centre, York Science Park, Heslington, York YO10 5DF (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/100426 A1

(54) Title: BMP BINDING PROTEINS FOR USE IN BONE OR CARTILAGE REGENERATION

(57) Abstract: A medicament or device for tissue regeneration, for example bone and/or cartilage tissue, in which the medicament or device comprises a BMP binding protein.

BMP BINDING PROTEINS FOR USE IN BONE OR CARTILAGE REGENERATION

The invention relates generally to the field of bone and cartilage biology and is concerned with the provision of methods, pharmaceutical compositions/ medicaments and devices for promoting tissue, e.g. bone and/or cartilage, formation and to constructs such as prosthetic devices which comprise such compositions.

Bone

Vertebrate bone, as a tissue providing mechanical support for the body, undergoes constant remodelling through the formation and resorption of bone mediated, it is widely thought, by the activities of osteoblasts and osteoclasts respectively. Bone remodelling comprises a complex and highly organised interaction between cells and the extracellular matrix (ECM). The remodelling process is, however, adaptive in response to requirements of growth or habitual activity. In a normal healthy adult skeleton, the rate of bone formation approximates with the rate of bone resorption, through a process known as remodelling. Bone resorption or formation is not, though, a generalised feature of the entire skeleton simultaneously but occurs in discrete sites which may be surrounded by areas of quiescent bone. Where resorption occurs excessively, several clinical problems can occur either at a specific locality or more extensively throughout the skeleton.

For example, osteoporosis is a disease that is characterised by abnormalities in the amount and architectural arrangement of bone tissue. Osteoporosis is a major clinical condition that can lead to fractures of bone following only minimal trauma. Osteoporosis results from a shift in the balance of bone resorption and formation towards

resorption so that there is net bone loss. In addition to the distress to sufferers, the direct hospital costs of osteoporosis have been estimated, in the U.S. only, to approach $13 billion and in the UK to approach £750 million. The term 'osteoporosis' in fact refers to a group of conditions that are associated with loss of bone tissue and an accompanying architectural abnormality that occurs in cancellous bone space. When the condition develops in post-menopausal women it is referred to as postmenopausal osteoporosis. Fractures occur commonly in the hip, spine and distal radius and are considered in many countries to be a major public health problem (Lindsay R (1993), Clinical Rheumatology Osteoporosis; V.7, No.3). While genetics, diet and life-style appear to be factors in the pathogenesis of the disease, loss of ovarian function is an important determinant, at least in postmenopausal osteoporosis.

One reason for the low bone formation in osteoporosis is a reduced number of active osteoblasts. Agents capable of increasing the number of these cells would therefore have utility in conditions characterised by low bone mass.

Other osteoporotic-associated disease states include steroid induced osteoporosis, idiopathic juvenile osteoporosis, and post-transplantation osteoporosis where bone resorption is a secondary indication of disorder.

In the disease known as Paget's disease, there is excessive osteoclastic resorption of bone which results in excessive osteoblastic bone formation leading to disorganised bone structure.

Long term bed rest or disability for reasons that may not necessarily be directly related to diseases of the bone can lead to bone loss and danger of fracture on remobilisation or rehabilitation.

In cancer, formation of primary and secondary tumours often cause resorption and/or formation and subsequent increased liability to fracture or loss of function.

Tumour-induced osteolysis may also lead to pathologically raised serum calcium levels, which are believed to increase significantly morbidity in cancer patients.

Several approaches have been taken to treat low bone mass which are based on the use of anti-resorptive agents such as bisphosphonates that reduce or inhibit bone loss but none of these approaches are entirely satisfactory since the subsequent increase in bone formation occurs slowly.

The use of bisphosphonates to inhibit bone resorption is also not ideal since the degree of side effects is regarded by some as unacceptably high and its use is not well tolerated by a significant proportion of the population.

Oestrogen and other hormone replacements have a history of use for postmenopausal osteoporosis, either alone or in combination with other therapeutics. However suggestions of an increased risk of endometrial and breast cancer, as well as the continuation of menstrual bleeding, which is often unwelcome in the elderly female section of the population who form the majority of sufferers of osteoporosis, has provided a need for an alternative approach.

Other treatments for osteoporosis employing agents which affect osteoclast function have been used e.g. calcitonin or parathyroid hormone but with limited success.

As well as diseases and conditions which affect the rate of bone regeneration, physical knocks and accidents may also cause bone fractures.

The rate of bone fractures in the United States alone, is estimated at 6 millions individuals per year.

The most well established method for bone repair is the mechanical one, and this typically involves hard implants and hardware, such as plates, pins and screws. Within the category of hard implants, there exist an array of plastics, organic-based synthetic cements and metal prostheses. There are two major considerations and concerns in using mechanical hardware and implants. The first relates to the effectiveness of the physiological integration of the hardware into the body systems, while the second is that of the long-term durability of the non-biological material which has been implanted. Despite these problems, mechanical implants are very popular, and, while not comprising living bone tissue, make significant contributions assisting in the bone reconstruction.

When a bone is completely fractured, a significant proportion of fractures require medical intervention beyond simple immobilisation (casting). A major problem in such instances is the lack of proximity of the two bone ends. This results in an inappropriate and prolonged repair process, which may prevent recovery. The average length of time for the body to repair a fracture is 25 – 100 days, for moderate load-bearing, and one year for complete repair. Thus, both simple fractures and medically complicated breaks would benefit from novel therapeutic modalities which accelerate and/or complete the repair process. The same is true for those bone diseases (referred to as osteoporosis or osteopenias) which result in a thinning of the bone the primary symptom of which is an often-debilitating fracture.

Some work using exogenous growth factors such as bone morphogenic proteins (BMPs) has been done to aid bone regeneration. With this method extremely large amounts of growth factors e.g. BMPs are administered to the damaged bone site. This however suffers from the disadvantage that the large concentration of the growth factor can cause a shift in biological equilibrium, possibly making the growth factor less potent.

An additional problem of administering growth factors such as BMPs is that 90% of the exogenous growth factor can be excreted in the first twenty four hours suggesting that most of the growth factor is missing its target cell.

In previous work with BMPs and BMP binding protein e.g. follistatin it was believed that follistatin inhibited the action of BMP, upon binding to the BMP. (Follistatin, Ketan Patel, The International Journal of Biochemistry & Cell Biology 30 (1998) 1087-1093; Direct binding of Follistatin to a complex of bone-morphogenic protein and its receptor inhibits ventral and epidermal cell fates in early xenopus embryo, Shar-Lchiro Iemura etal, Proc. Natl. Acs. Sci. USA. Vol. 95 pp 9337-9342 August 1998 Developmental Biology.) The BMP binding protein e.g. follistatin would bind to the BMP, creating an inactive form of BMP, so it was believed. Therefore it was believed that BMP binding proteins e.g. follistatin inhibited bone formation by inhibiting the action of BMPs.

However we have surprisingly found against the teachings of established dogma that when conditions characterised by deficiency are treated by direct administration of BMP binding proteins, for example follistatin, cell differentiation and/or proliferation is promoted.

We have found that BMP binding proteins, for example follistatin, increases differentiation of stromal stem cells, myoblast and undifferentiated stromal cells to osteoblast cells.

Cartilage

Cartilage has a limited capacity for self repair.

The cartilage of the body can be damaged by physical knocks. Damaged cartilage is prone to further degeneration, i.e. osteoarthritis.

The disease osteoarthritis (OA) which is characterised by the destruction of articular cartilage can also occur without any minor injury. It affects at least 16 million Americans and is symptomatic in 80% of the populaton over 75 years of age. With an ageing population its relevance is increasing and becoming more of a burden on healthcare services.

A major constituent of cartilage is collagen.

Collagen is one of the most abundant animal proteins in nature. It is present in all types of multicellular animals, including humans, where it is estimated to account for about 30% of the total human body protein. Collagen constitutes the fibrillar component of the soft connective tissues (e.g., skin, ligament, and tendon) and is the major component of the organic matrix of calcified tissues such as bone and dentine. In addition to its structural significance, collagen plays an important role in development and wound healing, and has been implicated in ageing and some disease processes.

There are several genetically distinct types of collagen, which are referred to as types I, II, III, and so forth. Type II collagen is the major collagen of cartilage. It is synthesised by chondrocytes as a

procollagen molecule with noncollagenous aminopropeptide and carboxypeptide extensions. These two extensions are removed by specific peptideases before type II collagen is incorporated into fibrils.

By the term cartilage we mean any cartilage of the animal or human body including but not limited to: articular, hyaline, meniscal and yellow-elastic cartilage.

There is thus a need for a means to increase cartilage growth, repair and regeneration.

In a further aspect of the present invention it is an object to provide a novel tissue regeneration method.

It is an object of a further aspect of the present invention to provide a composition to aid tissue regeneration.

It is an object of the present invention to provide compositions for promoting bone formation which is an alternative to current and proposed therapies such as the bisphosphonates, parathyroid hormone (PTH) and its derivatives for treating bone deficiency and abnormalities.

It is an object of the present invention to provide a scaffold to bind Bone Morphogenic Proteins (BMPs) for controlled release of BMPs.

It is a further object of the present invention to provide a method of controlled release of bound BMPs.

It is an object of a further aspect of the present invention to provide a scaffold to aid tissue regeneration.

It is an object of the present invention to provide a novel cartilage regeneration method.

It is an object of the present invention to provide a scaffold to aid cartilage regeneration.

It is an object of the present invention to provide a scaffold that aids endogenous or exogenous BMPs to reach their target cells.

It is an object of the present invention to provide a scaffold for cartilage formation which is an alternative to current and proposed therapies such as mosaic plasty, autologous chondrocyte implantation and tissue engineering.

According to the present invention there is provided a medicament comprising a BMP binding protein.

Also according to the present invention there is provided a medicament comprising a BMP binding protein to aid tissue regeneration.

In this application the term "medicament" and "pharmaceutical composition are to be taken as equivalent meaning.

By the term BMP binding protein we mean any protein able to bind to the BMP family of proteins. Preferably the BMP binding protein would bind to the BMP enhancing the activity of the BMP e.g. enhancing tissue regeneration. The term BMP binding protein is to include but by no means be limited to the proteins; Follistatin, Follistatin Related Protein (FSRP), FLIK, Alpha-2-HS-glycoprotein, Collagen IIa, Collagen IV, Collagen V Alpha 1, Collagen V Alpha 2,

Chordin, Sog, Crim, Nell, Connective Tissue Growth Factor (CTGF), Dan, Gremlin, Cerberus, Endoglin, Twisted Gastulation gene, ZFSTA2 and derivatives, fragments and/or analogues thereof, of the before mentioned proteins.

A typical group of BMP binding proteins include the "Follistatin" group, which includes Follistatin, Follistatin Related Protein (FSRP), ZFSTA2, FLIK, and derivatives, fragments and/or analogues thereof, of the before mentioned BMP proteins.

Another typical group of BMP binding proteins include the "Cystein rich" BMP binding proteins, which include, Collagen IIa, Collagen IV, Collagen V Alpha 1, Collagen V Alpha 2, Chordin, Sog, Crim, Nell, Connective Tissue Growth Factor (CTGF) and derivatives, fragments and/or analogues thereof, of the before mentioned BMP proteins.

Another typical group of BMP binding proteins include the "Cerberus" BMP binding proteins, which include Cerberus, Gremlin, Dan and derivatives, fragments and analogues thereof, of the before mentioned BMP proteins.

An apt group of BMP binding proteins also include Follistatin, Collagen IIa, Collagen IV, Chordin, Nell, Crim and derivatives, fragments and analogues thereof, of the before mentioned proteins.

Apt BMP binding proteins include Follistatin, FLIK, Collagen IIa. Collagen IV, Collagen V Alpha 1, Collagen V Alpha 2, Endoglin, Dan, Gremlin, Cerberus, Chordin, Sog, Crim, Nell and derivatives, fragments and/or analogues thereof of the before mentioned proteins.

Typically the BMP binding protein may be follistatin or Collagen IIa, or derivatives, fragments and/or analogues thereof, of Follistatin or Collagen IIa.

Aptly the BMP binding protein will be follistatin. Or in certain aspects of the invention the BMP binding protein may be Collagen IIa. In further aspects of the invention the BMP binding protein may be Endoglin.

According to the present invention there is provided a pharmaceutical composition comprising a protein selected from the group:

Follistatin, FSRP, FLIK, ZFSTA2, Alpha-2-HS glycoprotein, Collagen Iia, Collagen IV, Collagen V Alpha 1, Collagen V Alpha 2, Chordin, Sog, Crim, Nell, Connective Tissue Growth Factor (CTGF), Dan, Gremlin, Cerberus, Endoglin, Noggin, Twisted Gastulation Gene, ZFSTA2 or derivatives, fragments and/or analogues thereof, of the before mentioned BMP proteins.

Also according to the present invention there is provided a pharmaceutical composition comprising a protein selected from the group:

Follistatin, FSRP, FLIK, Alpha-2-HS glycoprotein, Collagen IIa, Collagen IV, Collagen V Alpha 1, Collagen V Alpha 2, Chordin, Sog, Crim, Nell, Connective Tissue Growth Factor (CTGF), Dan, Gremlin, Cerberus, Endoglin, Noggin, Twisted Gastulation Gene, ZFSTA2 or derivatives, fragments and/or analogues thereof, of the before mentioned BMP proteins.

Suitable BMP binding proteins of the present invention include:
Follistatin,
FSRP,
ZFSTA2,
FLIK,
Alpha-2-HS glycoprotein,
Collagen Iia,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Chordin,
Sog,
Crim,
Nell,
Connective Tissue Growth Factor (CTGF),
Dan,
Gremlin,
Cerberus,
Endoglin,
Twisted Gastulation gene, or derivatives, fragments and/or analogues thereof, of the beforementioned BMP binding proteins.

Typically BMP binding proteins of the present invention include Follistatin, FLIK, Alpha-2-HS glycoprotein, Nell, Crim, Endoglin and derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding protein.

An apt group, for example, of BMP proteins of the present invention is the collagen type proteins Collagen IIa, Collagen IV, Collagen V Alpha 1 and Collagen Alpha 2 or derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding protein.

Another apt group, for example, of BMP proteins of the present invention is Endoglin, Dan, Sog, Crim, Nell and chordin or derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding protein.

Yet another apt group, for example, of BMP binding proteins of the present invention is Sog, Crim, Nell and derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding proteins.

Still yet another apt group, for example, of BMP binding proteins of the present invention is Cerberus, Chordin, FLIK and derivatives, fragments and/or analogues thereof.

Typically the BMP binding protein is Follistatin.

Typically the BMP binding protein is Collagen IIa, or derivatives, fragments and/or analogues thereof.

In certain aspects of the present invention the BMP binding protein is Crim, or derivatives, fragments or analogues thereof. In other aspects of the present invention the BMP binding protein is Dan, or derivatives, fragments and/or analogues thereof. In particular embodiments of the present invention the BMP binding protein is ZFSTA2, or derivatives, fragments or analogues thereof. In other embodiments of the present invention the BMP binding protein is Endoglin, or derivatives, fragments or analogues thereof. Likewise the BMP binding protein of the present invention may be Nell or derivatives, fragments or analogues thereof. Alternative embodiments of the present invention may have the BMP binding

protein Nell, or derivatives, fragments or analogues thereof, as the BMP binding protein.

By the term BMP we mean the BMP super family of bone morphogenic proteins, this includes but is not limited to:-

BMP-2,
BMP-3,
BMP-3B/GDF-10,
BMP-4,
BMP-5,
BMP-6,
BMP-7/OP-1,
BMP-8/ OP-2,
BMP-8B,
BMP-9,
BMP-10,
BMP-11,
BMP-12,
BMP-13,
BMP-14,

CDMP-1,
CDMP-2,
CDMP-3,

GDF-1,
GDF-2,
GDF-3
GDF-4
GDF-5/CDMP-1/BMP-14,
GDF-6/CDMP-2/BMP-13,

GDF-7/CDMP-3/BMP-12,
GDF-8,
GDF-9,

In certain aspects of the present invention the BMPs may be, for instance, endogenous BMPs found naturally in the body, or may be natural BMPs added to the treatment site. In other aspects of the present invention, for instance, the BMPs may be or may include recombinant BMPs.

Suitable BMPs include BMP-2, BMP-5, BMP-4, BMP-6 and BMP-7.

A typical group of BMPs includes BMP-5, BMP-6, BMP7, BMP8/OP-2 and BMP-8B. Another typical group of BMPs include BMP-2 and BMP-4. Another typical group of BMPs also include BMP3 and BMP3B/GDF-10. Also, a typical group of BMPs include GDF-5/CDMP-1/BMP-14, GDF-6/CDMP-2/BMP13, GDF-7/CDMP-3/BMP-12. Typically the BMP may be GDF-9. Also the BMP may be GDF3 in other embodiments of the invention. Aptly the BMPs of the invention may include BMP-2, BMP-4, BMP-6 and BMP-7.

In particular embodiments of the present invention the BMPs may be a mix of endogenous BMPs found at the treatment site. In other aspects of the present invention recombinant BMPs may be added to the treatment site, or to the make up of the devive according to the present invention to ensure the presence of BMPs. The BMPs may include, BMP-2 in certain embodiments of the present invention. Or may include BMP-4 in certain embodiments of the present invention. Alternatively in other embodiments of the present invention the BMP may be BMP-7. Likewise in other embodiments the BMP may be BMP- 6.

Also according to embodiments of the present invention there is provided a medicament comprising a BMP binding protein.

There is further according to the present invention a medicament comprising a BMP binding protein selected from the group:

Follistatin
FSRP,
FLIK,
ZFSTA2,
Alpha-2-HS glycoprotein,
Collagen IIa,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Chordin,
Sog,
Crim,
Nell,
Connective Tissue Growth Factor (CTGF),
Dan,
Gremlin,
Cerberus,
Endoglin,

Twisted Gastulation Gene, or derivatives, fragments and/or analogues thereof, of the BMP binding proteins here before mentioned.

Further still according to the present invention there is provided a medicament comprising a BMP binding protein selected from the group:

Follistatin,
FSRP,
ZFSTA2,
FLIK,
Collagen IIa,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Endoglin,
Dan,
Gremlin,
Cerberus,
Chordin,
Sog,
Crim,
Nell, or derivatives, fragments and/or analogues thereofof the before mentioned BMP binding proteins.

Such a medicament may be to treat tissue regeneration, for example bone and/or cartilage tissue regeneration.

According to the present invention there is provided a pharmaceutical composition comprising a protein selected from the group: follistatin, a protein described in the amino acid sequence (I), or derivatives, fragments and/or analogues thereof.

Also according to the present invention there is provided a pharmaceutical composition for promoting tissue generation in which

the pharmaceutical composition comprises a protein selected from the group: follistatin, a protein described in the amino acid sequence (I) listed below, or derivatives, fragments and/or analogues thereof.

The sequence (I) is:

(I)

1 mvrarhqpgg lcllllllcq fmedrsaqa-g ncwlrqakng rcqvlyktel skeeccstgr
61 lstswteedv ndntlfkwmi fnggapncip cketcenvdc gpgkkcrmnk knkprcvcap
121 dcsnitwkgp vcgldgktyr necallkarc keqpelevqy qgrckktcrd vfcpgsstcv
181 vdqtnnaycv tcnricpepa sseqylcgnd gvtyssachl rkatcllgrs iglayegkci
241 kakscediqc tggkkclwdf kvgrgrcslc delcpdsksd epvcasdnat yasecamkea
301 acssgvllev khsgscneee eededqdysf pissilew

Suitably the tissue may be bone tissue, and thus the present invention may be used to promote bone growth. The tissue may also be tissue of the central nervous system and thus the present invention may be used to promote growth and/or repair of the central nervous system to, for example, aid stroke recovery of a patient.

The tissue may also be chondrocyte/cartilage tissue and thus the present invention may be used to promote growth and/or repair of cartilage.

Also according to the present invention there is provided a medicament comprising a protein selected from the group: follistatin, a protein described in the amino acid sequence (I), or fragments and/or analogues thereof.

There is, further according to the present invention, provided a medicament for the treatment of diseases or clinical conditions featuring or characterised by bone deficiency comprising a protein selected from the group: follistatin, a protein described in the amino acid sequence (I), or fragments thereof.

Also according to the present invention there is provided the use of a BMP binding protein, in the manufacture of a medicament for the treatment of diseases or clinical conditions that may be alleviated by the promotion of tissue regeneration, e.g. cartilage and/or bone tissue regeneration.

Further according to the present invention there is provided the use of a BMP binding protein in the manufacture of a medicament for the treatment of diseases or clinical conditions that may be alleviated by the promotion of tissue regeneration e.g. cartilage and/or bone tissue regeneration, in which the protein is selected from the group:

Follistatin,
FSRP,
ZFSTA2,
FLIK,
Alpha-2-HS glycoprotein,
Collagen IIa,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Chordin,
Sog,
Crim,
Nell,
Connective Tissue Growth Factor (CTGF),

Dan,
Gremlin,
Cerberus,
Endoglin,
Twisted Gastulation Gene, or derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding proteins.

Further still according to the present invention there is provided the use of a BMP binding protein in the manufacture of a medicament for the treatment of diseases or clinical conditions that may be alleviated by the promotion of tissue regeneration e.g. cartilage and/or bone tissue regeneration, in which the protein is selected from the group

Follistatin,
FSRP,
ZFSTA2,
FLIK,
Alpha-2-HS glycoprotein,
Collagen IIa,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Endoglin,
Dan,
Gremlin,
Cerberus,
Chordin,
Sog,
Crim,
Nell, or derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding proteins.

Accordingly there is provided the use of a protein which is capable of binding BMPs in the manufacture of a medicament for the treatment of diseases or clinical conditions that may be alleviated by the promotion of bone formation in which the protein is selected from the group: follistatin, a protein described in the amino acid sequence (I) listed herein, or fragments and/or analogues thereof.

Accordingly there is provided the use of a protein which is capable of binding BMPs in the manufacture of a medicament for the treatment of diseases or clinical conditions that may be alleviated by the promotion of tissue generation e.g. bone formation, cartilage formation or formation of tissue of the central nervous system, in which the protein is selected from the group: follistatin, a protein described in the amino acid sequence (I) listed below, or fragments and/or analogues thereof.

In another aspect of the present invention there is provided a method for the treatment of diseases or clinical conditions that may be alleviated by the promotion of bone formation comprising the step of administering a therapeutically effective amount of a protein which is capable of binding BMPs in which the protein is selected from the group: follistatin, a protein described in the amino acid sequence (I) listed herein, or fragments and/or analogues thereof.

In a further aspect of the present invention, there is provided a method for the prevention of diseases or clinical conditions that may

be alleviated by the promotion of bone formation comprising the step of administering a therapeutically effective amount of a protein which is capable of binding BMPs in which the protein is selected from the group: follistatin, a protein described in the amino acid sequence (I) listed below, or fragments and/or analogues thereof.

In a further aspect of the present invention there is provided a method for promoting bone formation comprising the step of administering a therapeutically effective amount of a protein which is capable of binding BMPs in which the protein is selected from the group: follistatin, a protein described in the amino acid sequence (I) listed below, or fragments and/or analogues thereof.

In another aspect of the present invention there is provided a method for the prevention or treatment or of diseases or clinical conditions that may be alleviated by the promotion of tissue formation, e.g. bone, cartilage or tissue of the central nervous system, comprising the step of administering a therapeutically effective amount of a protein which is capable of binding BMPs in which the protein is selected from the group: follistatin, a protein described in the amino acid sequence (I) listed below, or fragments and/or analogues thereof.

In another aspect of the present invention there is provided a method for the prevention or treatment or of diseases or clinical conditions that may be alleviated by the promotion of tissue formation, for example, bone, cartilage or tissue of the central nervous system, comprising the step of administering a therapeutically effective amount of a BMP binding protein.

In other aspects, methods of diagnosis and diagnostic kits are provided. Diagnostic methods and kits based on assays for the proteins of the present invention or their derivatives or breakdown products in bodily samples (e.g. blood, urine, bone biopsies, marrow cell biopsies) are provided.

Furthermore, the use of the present proteins in the use of DNA based screening techniques (so called "DNA fingerprinting") to identify genetic polymorphisms, mutations, deletions or other alterations in an individual's genotype is provided in the present invention to identify persons at risk from bone disorders e.g. bone loss.

Although it is envisaged that this invention will benefit bone fracture repair, it may be used to treat other clinical conditions and diseases.

Clinical conditions and diseases of bone loss that may benefit from this invention include but not restricted to; osteoporosis, (including osteoporosis of disuse, Schüller's disease, post-menopausal osteoporosis, post-traumatic osteoporosis, senile osteoporosis), Paget's disease, undesired bone resorption featured in cancer and renal disease and rheumatoid arthritis.

It is envisaged that the present invention can be used to treat bone repair, or induce bone growth without a large concentration of the BMP binding growth factor being needed. Using large concentrations of growth factors has been a problem to date as this suffers from the disadvantage that a large concentration of the growth factor (as noted above), can cause a shift in biological equilibrium possibly making the growth factor less potent.

The present invention enables better targeting of BMP on its target cell.

An additional problem of administering growth factors such as BMPs is that 90% of the exogenous growth factor can be excreted in the first twenty four hours suggesting that most of the growth factor is missing its target cell.

Suitable proteins for use in the present invention include follistatin and derivatives thereof. In particular proteins of the present invention include the amino acids described in amino acid sequence (I) listed below and/or fragments or analogues thereof.

(I)

1 mvrarhqpgg lcllllllcq fmedrsaqa-g ncwlrqaknq rcqvlyktel skeeccstgr
61 lstswteedv ndntlfkwmi fnggapncip cketcenvdc gpgkkcrmnk knkprcvcap
121 dcsnitwkgp vcgldgktyr necallkarc keqpelevqy qgrckktcrd vfcpgsstcv
181 vdqtnnaycv tcnricpepa sseqylcgnd gvtyssachl rkatcllgrs iglayegkci
241 kakscediqc tggkkclwdf kvgrgrcslc delcpdsksd epvcasdnat yasecamkea
301 acssgvllev khsgscneee eededqdysf pissilew

Also according to the present invention there is provided a pharmaceutical composition for promoting tissue generation in which the pharmaceutical composition comprises a protein selected from the group: collagen IIa, a protein described in the amino acid sequence (II) listed below, or derivatives, fragments and/or analogues thereof.

Suitable proteins for use in the present invention include collagen IIa and derivatives thereof. In particular proteins of the present invention include the amino acids described in amino acid sequence (II) listed below and/or fragments or analogues thereof.

The sequence (II) is:

1 mirlgapqsl vlltllvaav lrcqgqdvqe agscvqdgqr
yndkdvwkpe pcricvcdtg
61 tvlcddiice dvkdclspei pfgeccpicp tdlatasgqp
gpkgqkgepg dikdivgpkg
121 ppgpqgpage qgprgdrgdk gekgapgprg rdgepgtpgn
pgppgppgpp gppglggnfa
181 aqmaggfdek aggaqlgvmq gpmgpmgprg ppgpagapgp
qgfqgnpgep gepgvsgpmg
241 prgppgppgk pgddgeagkp gkagergppg pqgargfpgt
pglpgvkghr gypgldgakg
301 eagapgvkge sgspgengsp gpmgprglpg ergrtgpaga
agargndgqp gpagppgpvg
361 paggpgfpga pgakgeagpt gargpegaqg prgepgtpgs
pgpagasgnp gtdgipgakg
421 sagapgiaga pgfpgprgpp gpqgatgplg pkgqtgepgi
agfkgeqgpk gepgpagpqg
481 apgpageegk rgargepggv gpigppgerg apgnrgfpgq
dglagpkgap gergpsglag
541 pkgangdpgr pgepglpgar gltgrpgdag pqgkvgpsga
pgedgrpgpp gpqgargqpg
601 vmgfpgpkga ngepgkagek glpgapglrg lpgkdgetga
agppgpagpa gergeqgapg
661 psgfqglpgp pgppgeggkp gdqgvpgeag apglvgprge
rgfpgergsp gaqglqgprg
721 lpgtpgtdgp kgasgpagpp gaqgppglqg mpgergaagi
agpkgdrgdv gekgpegapg
781 kdggrgltgp igppgpagan gekgevgppg pagsagarga
pgergetgpp gpagfagppg
841 adgqpgakge qgeagqkgda gapgpqgpsg apgpqgptgv
tgpkgargaq gppgatgfpg
901 aagrvgppgs ngnpgppgpp gpsgkdgpkg argdsgppgr
agepglqgpa gppgekgepg
961 ddgpsgaegp pgpqglagqr givglpgqrg ergfpglpgp
sgepgkqgap gasgdrgppg
1021 pvgppgltgp agepgregsp gadgppgrdg aagvkgdrge
tgavgapgap gppgspgpag

1081 ptgkqgdrge agaqgpmgps gpagargiqg pqgprgdkge agepgerglk ghrgftglqg
1141 lpgppgpsgd qgasgpagps gprgppgpvg psgkdgangi pgpigppgpr grsgetgpag
1201 ppgnpgppgp pgppgpgidm safaglgpre kgpdplqymr adqaagglrq hdaevdatlk
1261 slnnqiesir spegsrknpa rtcrdlklch pewksgdywi dpnqgctlda mkvfcnmetg
1321 etcvypnpan vpkknwwssk skekkhiwfg etinggfhfs ygddnlapnt anvqmtflrl
1381 lstegsqnit yhcknsiayl deaagnlkka lliqgsndve iraegnsrft ytalkdgctk
1441 htgkwgktvi eyrsqktsrl piidiapmdi ggpeqefgvd igpvcfl

A typical protein of the present invention is a material which has an amino acid sequence of amino acid sequences (I) described above and preferably the agent will be a peptide or protein per se; functionally active fragments and analogues thereof; homologues having a high degrees of conservation, in particular those with conserved cysteine regions and vectors therefore such as DNA vectors (plasmids or viruses) which encode peptides and proteins containing an amino acid sequence described in amino acid sequence (I).

Functionally active fragments and analogues may be formed by the addition, insertion, modification, substitution or deletion of one or more of the amino acid residues from or to an amino acid sequence described in amino acid sequence (I) listed above.

The term "analogue" is also intended to embrace chimeric proteins, fusion proteins, antidiotypic antibodies, precursor and other functional equivalents or mimics to the above. Also synthetic entities that mimic the activity of BMP binding proteins.

The use of the amino acid sequences (I) listed above or a functionally active fragment or analogue thereof is also provided in the manufacture for a medicament for promoting bone formation.

There is also provided a method of promoting tissue regeneration e.g. bone and/or cartilage regeneration comprising of the step of administering a BMP binding protein.

Also provided is a method of promoting tissue regeneration e.g. bone and/or cartilage regeneration comprising the steps of administering a BMP binding protein in which the BMP binding protein is selected from the group:

Follistatin,
FSRP,
ZFSTA2,
FLIK,
Alpha-2-HS glycoprotein,
Collagen IIa,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Chordin,
Sog
Crim,
Nell
Connective Tissue Growth Factor (CTGF),
Dan,
Gremlin,
Cerberus,
Endoglin

Twisted Gastulation gene, or derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding proteins.

There is further provided a method of promoting bone formation in a, preferably, mammalian patient comprising the step of; administering an effective amount of an amino acid sequences (I) listed above or a functionally active fragment or analogue, thereof.

Use of DNA vectors expressing cDNA of the protein of the present invention and fragments thereof, and cells transfected with constructs expressing said cDNA for promoting bone formation also forms an aspect of the present invention. cDNA and transfected cells as described above may be prepared according to standard techniques known to those skilled in the art.

The present invention further extends to gene therapy for promoting bone formation in, preferably, a mammalian patient in clinical need thereof.

The protein of the present invention may be coupled to a "bone-seeking" substance such as a tetracycline or bisphosphonates to improve target specificity as known by those skilled in the art.

Function manipulating agents of the present invention may be manufactured according to any appropriate method of choice. Such methods include synthetic or recombinant methods or purification methods, if available, from natural sources.

Pharmaceutical compositions of the present invention may be prepared according to methods well known and called for by accepted pharmaceutical practice. Pharmaceutical compositions suitably comprise the protein of the present invention together with a

pharmaceutically acceptable carrier and are suitably in unit dosage form. Pharmaceutical compositions of the present invention may comprise a protein of the present invention in the form of a pro-drug which can be metabolically converted to the active form of the invention agent by the recipient host.

Pharmaceutical compositions of the present invention may also be used in conjunction, e.g. simultaneously, sequentially or separately with other therapies, for example, the bisphosphonates. Pharmaceutical compositions of the present invention may comprise other active agents such as bisphosphonates, PTH, vitamin D, BMPs and oestrogen.

In another aspect, we also provide a medical device, e.g. bone screw, endoprosthesis such as a hip prosthesis, or a trauma nail such as an intramedullary nail having a bone-contacting surface comprising a protein of the present invention.

Aptly the protein of the present invention will be present as a layer, for example as a coating on the bone-contacting surface of the device. Suitably, medical devices according to the present invention may be prepared by absorbing a protein of the present invention onto, for example, the titanium oxide or other surface of a metallic surface or of a polymer surface, e.g. bone screw, by incorporating the protein of the present invention into a carrier material and coating the carrier onto the medical device.

In an embodiment of this aspect of the present invention, the bone contacting surface has been 'derivatised' or modified such that the protein of the present invention is directly bonded, aptly by covalent bonds, to the surface.

In another aspect of the present invention we provide an artificial scaffold material for promoting bone formation, the scaffold having operatively coupled thereto a protein of the present invention.

The scaffold of the present invention may in the form of a three dimensional matrix or layer, for example, a continuous film, or gel. The matrix structure may be manufactured from fibres or a suitable material which is then textile processed (e.g. braided, knitted, woven or non-woven, melt-blown, felted, hydro-entangled) and further manipulated into a desired three dimensional shape. The matrix structure may also assume other forms, e.g. sponges or foams.

Suitable scaffold materials are preferably biodegradable and are not inhibitory to cell growth or proliferation. Typically the materials should not elicit an adverse reaction from the patients' body and should be capable of sterilisation by for example ethylene oxide treatment. Typically the material is osteoconductive.

Suitable materials therefore include biodegradable polyesters such as polylactic acid (PLA), polyglycolic acid (PGA), polydioxanone, polyhydroxyalkanoates, e.g. polyhydroxbutyrate (ICI) and hyaluronic acid derivatives, e.g. HYAFF (Fidia). Further suitable materials include those disclosed in our patent applications WO 91/13638 and WO 97/06835, incorporated herein by reference such as hydrophilic polyurethanes, polyetherpolyester, polyethylene oxide, polyetherpolyamide, carboxymethylcellulose, ethylene-vinyl acetate copolymers, polybutadiene, styrene-butadiene-styrene block copolymers and the like.

Other scaffold materials are collagen based e.g. cross-linked collagen/elastin material, cross-linked collagens manufactured from acid-soluble type I bovine collagen sources, collagen gels, (for

example those sold under the trade names COLLASTAT and COLETICA). Collagen from natural or recombinant sources may be used.

Modified or chimeric recombinant fibrillar collagens (herein "modified collagen") are also provided which incorporate a protein from the present invention and features that promote its assembly, stability and use as a biomaterial. The modified collagen may be used as a scaffold material described supra. Approaches include use of the C-terminal globular domain from type I collagen to promote triple helix formation; the removal or alteration of the collagenase cleavage site to suppress degradation; the inclusion of additional lysines to promote cross-linking and the alternation of N-terminal globular domain cleavage site to promote the retention of the N-terminal domain in the mature fibre. For example, the chordin/SOG sequence of collagen IIa could be substituted for the protein/polypeptide function manipulating agent. Analogous domain shuffling approaches may be used to incorporate a protein of the present invention into other extracellular matrix components (e.g. fibronectin link protein or collagen IV) or ECM binding molecules or sequences (e.g. heparin binding domains). See, for example, WO 97/08311, the entire content of which are incorporated herein by reference.

In other specific embodiments, we provide a bone substitute material comprising a composite material comprising any one of the above scaffold materials and a crystalline phase (e.g. an apatite such as hydroxyapatite) incorporating a protein of the present invention.

In a suitable aspect of the present invention the protein of the present invention is delivered as a scaffold in the form of a gel.

Typically the gel will comprise thrombin, fibrinogen and Factor XIII or another transglutaminase to cross-link the gel.

The present invention also covers the development of animal models useful in the investigation of tissue for example bone disorders. The role of the protein of the present invention in the skeletal system may be investigated using non-human mammalian, e.g. mouse.

Suitably the protein would be bound to a solid matrix and implanted to the desired orthopaedic site. The trauma of this operation, the implanting of the protein bound matrix causes the production of BMPs which will bind onto the matrix due to the interaction of BMP and the protein of the present invention.

The protein of the present invention, preferably bound to a solid matrix, has the advantage over the prior art that excess BMPs produced naturally in the body are not wasted. Excess BMPs are usually quickly excreted from the body. The present invention concentrates BMPs, that may be produced naturally in the body and would normally be quickly excreted.

Accordingly to the present invention there is provided a scaffold comprising collagen IIa.

Also according to the present invention there is provided a scaffold for promoting tissue generation in which the scaffold comprises a BMP binding protein.

Also accordingly to the present invention there is provided a scaffold for promoting tissue generation in which the scaffold comprises collagen IIa.

Aptly the scaffold device is made entirely or substantially of collagen IIa, or is substantially coated with collagen IIa.

According to the present invention there is provided a scaffold comprising collagen IIa in which the scaffold is capable of releasably binding BMPs and capable of controlled release of BMPs.

Thus BMPs targeting is improved.

In particular embodiments the bound BMPs, once bound, may be released through normal cell activity and/or through a manipulating means, or agent, that can release the bound BMPs. The BMPs may be released through degradation of the scaffold.

Suitably the present invention will enable the soluble BMPs to interact with target cells e.g. in the defect healing site and, in embodiments where the target cells are capable of forming cartilage, to induce these target cells to express and synthesise cartilage components and thus to heal the defect site.

However the BMP need not necessarily be released for the invention to work as in particular embodiments of the present invention the BMP may still be active in a bound form.

Continued interaction of BMP and the formal cartilage type cells can lead to bone formation.

Bone may form through a process of endochondrial ossification through which cartilage is laid down first and is then mineralised. In this way bone forms through cartilage formation and therefore any treatment that is found to heal bone can be presumed to stimulate

cartilage formation and it can also be assumed that the converse is true.

In another aspect of the present invention there is provided a method for the treatment of diseases or clinical conditions that may be alleviated by the promotion of cartilage formation comprising the step of administering a scaffold comprising a therapeutically effective amount of collagen IIa in which the collagen IIa is capable of binding BMPs.

In a further aspect of the present invention, there is provided a method for the prevention of diseases or clinical conditions that may be alleviated by the promotion of cartilage formation comprising the step of administering a scaffold comprising a therapeutically effective amount of collagen IIa in which the collagen IIa is capable of binding BMPs.

In a further aspect of the present invention there is provided a method for promoting cartilage formation comprising the step of administering a scaffold comprising a therapeutically effective amount of collagen IIa in which the collagen IIa is capable of binding BMPs.

Although it is envisaged that this invention will benefit cartilage repair, it may be used to treat other clinical conditions and diseases.

Clinical conditions and diseases of cartilage loss that may benefit from this invention include; osteoarthritis, branchypodism and Hunter-Thompson chondrodysplasia. It may also be used to treat lesions in articular cartilage including those limited to the cartilage and those that penetrate the subchondral bone, and also OA.

It is envisaged that the present invention can be used to treat cartilage repair, or induce cartilage growth without a large concentration of the growth factor being needed. Using large concentrations of growth factors has been a problem to date as this suffers from the disadvantage that large concentration of the growth factor as noted above, can cause a shift in biological equilibrium possibly making the growth factor less potent.

The present invention enables better targeting of BMP on its target cell.

An additional problem of administering growth factors such as BMPs is that 90% of the exogenous growth factor can be excreted in the first twenty four hours suggesting that most of the growth factor is missing its target cell.

Aptly the collagen IIa or the scaffold of the present invention will be present as a layer, for example as a coating on the cartilage-contacting surface of a device. Suitably, medical devices according to the present invention may be prepared by absorbing collagen IIa or a scaffold of the present invention onto the surface of a e.g. cartilage anchor pin, by incorporating collagen IIa or a scaffold of the present invention into a carrier material and coating the carrier onto the medical device.

Similarly collagen IIa or the scaffold of particular aspects of the present invention may be used to promote bone regeneration.

There is also provided a method of manufacturing a scaffold for promoting tissue engineering comprising the step of: coating a scaffold with a BMP binding protein.

In an embodiment of this aspect of the present invention, the cartilage-contacting surface has been 'derivatised' or modified such that collagen IIa or a scaffold of the present invention is directly bonded, aptly by covalent bonds, to the surface.

The scaffold of the present invention may in the form of a three dimensional matrix or layer, for example, a continuous film, or gel. The matrix structure may be manufactured from fibres or a suitable material which is then textile processed (e.g. braided, knitted, woven or non-woven, melt-blown, felted, hydro-entangled) and further manipulated into a desired three dimensional shape. The matrix structure may also assume other forms, e.g. sponges or foams onto which the collagen IIa can be coated or bound onto the surface of the scaffold.

Suitable scaffold materials are preferably biodegradable and are not inhibitory to cell growth or proliferation. Preferably the materials should not elicit an adverse reaction from the patients' body and should be capable of sterilisation by e.g. ethylene oxide treatment. Preferably the material is osteoconductive.

Other scaffold materials are collagen based e.g. cross-linked collagen/elastin material, cross-linked collagens manufactured from acid-soluble type I bovine collagen sources, collagen gels, (for example those sold under the trade names COLLASTAT and COLETICA). Collagen from natural or recombinant sources may be used e.g. collagen IIa.

Modified or chimeric recombinant fibrillar collagens (herein "modified collagen") are also provided which incorporate collagen IIa and features that promote its assembly, stability and use as a biomaterial. The modified collagen may be used as a scaffold

material described supra. Approaches include use of the C-terminal globular domain from type I collagen to promote triple helix formation; the removal or alteration of the collagenase cleavage site to suppress degradation; the inclusion of additional lysines to promote cross-linking and the alternation of N-terminal globular domain cleavage site to promote the retention of the N-terminal domain in the mature fibre. For example, the chordin/SOG sequence of collagen IIa could be substituted for the protein/polypeptide function manipulating agent. Analogous domain shuffling approaches may be used to incorporate a protein of the present invention into other extracellular matrix components (e.g. fibronectin link protein or collagen IV) or ECM binding molecules or sequences (e.g. heparin binding domains). See, for example, WO 97/08311, the entire content of which are incorporated herein by reference.

In other specific embodiments, we provide a cartilage substitute material comprising a composite material comprising any one of the above scaffold materials and a ceramic osteoconductive or osteoinductive phase (e.g. an apatite such as hydroxyapatite) incorporating a BMP bonding protein for example collagen IIa.

In other specific embodiments, we provide a bone substitute material comprising a composite material comprising any one of the above scaffold materials and a ceramic osteoconductive or osteoinductive phase (e.g. an apatite such as hydroxyapatite) incorporating a BMP bonding protein for example collagen IIa.

In a suitable aspect of the present invention the scaffold of the present invention is delivered in the form of a gel. Typically the gel will comprise thrombin, fibrinogen and Factor XIII or another transglutaminase to cross-link the gel.

The present invention also covers the development of animal models useful in the investigation of cartilage disorders. The role of the protein of the present invention in the skeletal system may be investigated using non-human mammalian, e.g. mouse.

Suitably the BMP binding protein for example collagen IIa would be bound to a solid matrix to form the scaffold of the present invention and implanted to the desire orthopaedic site. It is assumed that the trauma of this operation, the implanting of BMP binding protein collagen IIa bound coated scaffold of the present invention causes the production of BMPs which will bind onto the scaffold due to the interaction of BMP and BMP binding protein collagen IIa on the scaffold of the present invention. The BMPs will be released through normal cell activity, allowing the now soluble BMP to interact with target cells stimulate proliferation and matrix production.

The scaffold of the present invention, has the advantage over the prior art that excess BMPs produced naturally in the body are not wasted. BMPs produced upon tissue trauma are not localised and present to the cells correctly. Current methods of administering BMPs by injecting BMPs to the damaged site does not overcome this problem as the BMPs are still not presented to the cells correctly. Excess BMPs are usually quickly excreted from the body. The present invention concentrates BMPs, that may be produced naturally in the body and would normally be quickly excreted, and allows the slow gradual release of these BMPs in the desired area. In some embodiments of the present invention there may be a slow gradual release of bound BMP to the scaffold of the present invention, where preferably collagen IIa itself is bound or coated to a solid matrix, and this may occur naturally in the body. Binding the BMP appears not to inactivate the BMP or cause any permanent damage to the BMP function.

The invention will now be described by way of example only with reference to the following examples, tables and drawings:

Figure 1.1 shows a bar chart of Alkaline Phosphatase Released per cell for cell samples containing Follistatin and BMP-2 ; against various controls.

Figure 1.2a shows the effect of follistatin on BMP-2 activity in C2C12 cells (solution experiment).

Figure 1.2b also shows the effect of follistatin on BMP-2 activity in C2C12 cells (solution experiment).

Figure 1.2c shows the effect of follistatin on BMP-5 activity in C2C12 cells (solution experiment).

Figure 1.2d shows the effect of follistatin on BMP-6 activity in C2C12 cells (solution experiment).

Figure 1.2e shows the effect of follistatin on BMP-7 activity in C2C12 cells (solution experiment).

Figure 1.3a shows the effect of follistatin on BMP-2 activity in C2C12 cells (bound experiment).

Figure 1.3b shows the effect of follistatin on BMP-6 activity in C2C12 cells (bound experiment).

Figure 1.3c also shows the effect of follistatin on BMP-6 activity in C2C12 cells (bound experiment).

Figure 1.3d shows the effect of follistatin on BMP-7 activity in C2C12 cells (bound experiment).

Figure 1.4 shows the effect of follistatin on BMP-4 activity in C2C12 cells (solution experiment).

Figure 1.5 shows the effect of follistatin on BMP-4 activity in C2C12 cells (bound experiment).

Figure 1.7 shows the effect of follistatin on BMP-2 activity in MC3T3EI cells (bound experiment).

Figure 1.8 shows the effect of follistatin 288 on BMP-2 activity in C2C12 cells (solution).

Figure 1.9 shows the effect of follistatin 288 on BMP-2 activity in C2C12 cells (bound).

Figure 1.10a shows a radiograph showing calcified tissue within the calf muscle of a rat treated with BMP-2 alone.

Figure 1.10b shows a radiograph showing calcified tissue within the calf muscle of a rat leg in which there can be see an increase in bone formation, over the control Figure 1.10a, when in the presence of follistatin and BMP-2.

Figure 1.10c shows photomicroscopy of a histology section stained with von Kossa and van Gieson counterstain of tissue implanted with follistatin and BMP-2 at x50 magnification.

Figure 1.10d shows photomicroscopy of a histology section stained with von Kossa and van Gieson counterstain of tissue implanted with follistatin and BMP-2 at x 100 magnification.

Figure 2.2a shows the effect of follistatin and BMP-2 on GAG production by chondrocytes.

Figure 2.2b shows the effect of follistatin and BMP-2 on collagen production by chondrocytes.

Figure 2.2c shows the effect of follistatin and BMP-2 on chondrocyte profliferation.

Figure 2.3a shows the effect of follistatin and BMP-2 on GAG production by chondrocytes in vitro (without ascorbate treatment).

Figure 2.3b show the effect of follistatin on cell morphology.

Figure 2.4 shows the effect of follistatin and OP-1 on GAG production by chondrocytes.

Sources of Recombinant Proteins for Experiments

Follistatin 300	a) R&D Systems Europe Abingdon OXON b) Produced on site at Smith &Nephew GRC, York Science Park, YORK
Follistatin 288	R&D Systems Europe Abingdon OXON
BMP-2	a) R&D Systems Europe Abingdon OXON b) NIBSC Potters Bar Hertfordshire

BMP-4 BMP-5 BMP-6 BMP-7	a) R&D Systems Europe Abingdon OXON

General Methods for Solution and Bound Experiments

Freeze-thaw Method for Lysing Cells: Media was removed from the cells and the cell layer was washed with 0.2 M carbonate buffer. The cells were lysed using a freeze thaw method adapted from Rago *et al.*, (DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem. 191: p31-34.1990). 100 µl of 0.1% triton X-100 in 0.2 M carbonate buffer was added to the wells. The plate was then frozen using liquid nitrogen and thawed at 37 °C a total of three times. The plate was examined under the optical microscope to ensure that all cells were lysed.

pNitrophenyl-Phosphate Alkaline Phosphatase Assay: Alkaline phosphatase activity was determined using an assay described by Leboy *et al.*, (Dexamethasone induction of osteoblast mRNA's in rat marrow stromal cell cultures. 1991, J Cell Physiol. 146: p370-378). The reaction involves the enzymatic cleavage of a phosphate group from p-nitro-phenyl-phosphate (pNPP) by alkaline phosphatase to give a coloured product, p-nitro-phenol (pNP). The absorbance of this product can be determined at 405nm using a microplate reader. Activities of alkaline phosphatase were calculated by interpolation from a dose response curve of standard pNP solutions, within a range of 0-250 nM ml^{-1} pNP.

PicoGreen Assay: Cell number was measured using the PicoGreen assay. This is a fluorometric assay that relies on the high sensitivity of PicoGreen for double stranded DNA. As each cell contains 7.7 pg

DNA, cell number can be calculated by the amount of DNA present. DNA standards were prepared at a range of 0-8 $\mu g\ ml^{-1}$. Absorbance was measured at an emmision wavelength of 485nm and an excitation wavelength of 538nm on a Microplate Reader. Microplate data were processed using a regression model to establish a standard curve derived from the standard DNA solutions, from which DNA concentrations can be determined.

Example 1.1 The effect of Follistatin and BMP-2 on C2C12 cells

The concentration of the BMP-2 used was approximately 1µg/ml. The concentration of the follistatin used was approximately 25µg/ml. The follistatin was found to be adherent to the well surface of the tissue culture plastic plate. This was incubated overnight, for approximately 16 hours, at 4°C. After incubation, the wells were washed three times with Phosphate Buffered Saline (PBS) to remove unbound follistatin. The BMP-2 was then incubated with the bound follistatin. After incubation, for 1 hour at 37°C, the mixture was removed and the wells washed three times with PBS to remove unbound BMP-2. C2C12 murine myoblasts were incubated with this mixture of proteins. These cultures were tested for alkaline phosphatase activity and a significantly increased level of alkaline phosphatase activity was observed compared to cultures without follistatin, indicating that the follistatin increases BMP-2 activity.

The Alkaline Phosphatase Assay was measured in triplicate for cell samples (1.06×10^4 $cell cm^{-2}$) with:

1. Follistatin
2. Follistatin and BMP-2
3. Tissue Culture Plastic (TCP)
4. BMP-2

5. Bovine Serum Albumin (BSA)
6. BSA and BMP-2.

The amount of total DNA for these samples was also measured, as DNA per pg/ml. As each cell contains 7.7 pg of DNA/ml, the total DNA amount was divided by 7.7 to give the average number of cells. The amount of Alkaline Phosphatase pmol/ml per cell, could then be calculated.

The enclosed table (Table 1.1) and graph (Figure 1.1) clearly show the substantial increase of Alkaline Phosphatase activity for the sample of cells treated with follistatin and BMP-2. Thus indicating increased bone cellformation.

Example 1.2: The effect of Follistatin and BMP-2, 5, 6 and 7 on C2C12 cells - Solution

BMP-2 and BMP-7 were prepared by diluting the contents of an ampoule with 1ml of serum free (SF) Dulbeccos Modified Eagle Medium (DMEM) to give a concentration of 10μgml^{-1}. This was further diluted to 5μgml^{-1} with SFDMEM.

BMP-6 was prepared by diluting the contents of an ampoule with 1ml of serum free SFDMEM to give a concentration of 20μgml^{-1}. This was further diluted to 5μgml^{-1} with SFDMEM.

BMP-5 was prepared by diluting the contents of an ampoule with 1ml of serum free SFDMEM to give a concentration of 50μgml^{-1}. This was further diluted to 5μgml^{-1} with SFDMEM.

The follistatin was prepared by diluting the contents of an ampoule with 3ml of SFDMEM to give a final concentration of 8.3μgml^{-1}.

C2C12 cells (ECACC lot 91031101) were removed from tissue culture flasks using trypsin/EDTA. Cell number and viability of the cells was assessed using trypan blue and a Neubauer haemocytometer. Cells were cultured at a cell density of 3.4×10^4 cells ml^{-1} (100µl per well in a 96 well plate, hence 1.06×10^4 cells/cm^2) and incubated at 37°C/5% CO_2 in a humidified atmosphere for 2 hours.

The following solutions were then added to the wells of a 96 well tissue culture plate (a minimum of four replicates per well):

For BMP-2 and Follistatin

Condition 1 - 40µl of follistatin + 60µl SFDMEM

Condition 2 - 40µl of follistatin + 20µl BMP-2 + 40µl SFDMEM

Condition 3 - 20µl BMP-2 + 80µl SFDMEM

Condition 4 - 100µl SFDMEM

For BMP-5 and Follistatin

Condition 1 - 40µl of follistatin + 60µl SFDMEM

Condition 2 - 40µl of follistatin +20µl BMP-5+ 40µl SFDMEM

Condition 3 - 20µl BMP-5 + 80µl SFDMEM

Condition 4 - 100µl SFDMEM

For BMP-6 and Follistatin

Condition 1 - 40µl of follistatin + 60µl SFDMEM

Condition 2 - 40µl of follistatin + 22.6µl BMP-6 + 37.4µl SFDMEM

Condition 3 - 22.6µl BMP-6 + 77.4µl SFDMEM

Condition 4 - 100µl SFDMEM

For BMP-7 and Follistatin

Condition 1 - 40µl of follistatin + 60µl SFDMEM

Condition 2 - 40μl of follistatin + 19.4μl BMP-7 + 40.6μl SFDMEM
Condition 3 - 19.4μl BMP-7 + 80.6μl SFDMEM
Condition 4 - 100μl SFDMEM

The plates were incubated at 37 °C /5% CO_2 for 4 days. After 4 days, the cells were lysed using the freeze thaw method. Alkaline phosphatase activity was assessed using the pNPP assay and cell number was measured using the PicoGreen assay as outlined in the general methods section.

The results are as seen in tables (1.2a to 1.2e) and as shown in Figures (1.2a to 1.2e).

As can be seen from these results the increase in alkaline phosphatase expressed by cultures grown in conditions of Follistatin and BMP, compared to those cultures grown in BMP alone, indicates that these cells have been stimulated to differentiate further along an osteoblastic lineage.

This result therefore suggests that cells respond to Follistatin and BMP resulting in a higher level of osteogenic tissue regeneration.

Example 1.3: The effect of Follistatin and BMP-2, 6 and 7 on C2C12 cells - bound

BMP-2 and BMP-7 were prepared by diluting the contents of an ampoule with 1ml of serum free SFDMEM to give a concentration of 10μgml^{-1}. This was further diluted to 1μgml^{-1} with SFDMEM.

BMP-6 was prepared by diluting the contents of an ampoule with 1ml of serum free SFDMEM to give a concentration of 20μgml^{-1}. This was further diluted to 1μgml^{-1} with SFDMEM.

The follistatin was prepared by diluting the contents of an ampoule with 3ml of SFDMEM to give a concentration of 8.3μgml^{-1}.

Four conditions were initially set up in wells of a 96 well plate (a minimum of four replicates for each condition):
Column 1) 50μl of Follistatin
Column 2) 50μl of Follistatin
Column 3) Tissue culture plastic (TCP)
Column 4) TCP

The above solutions were added to the wells of a 96 well tissue culture plate and left to incubate overnight at 4°C. Following incubation, the protein solutions were removed and the wells washed three times with PBS.

To the wells in conditions 2 and 3 (above) either 125.5μl/well of BMP-2 (1μg ml^{-1}) or 142.5μl/well of BMP-6 (1μg ml^{-1}) or 121.5μl/well of BMP-7 (1μg ml^{-1}) was added. 100μl/well of SFDMEM was added to the wells in conditions 1 and 4 (above). These solutions were allowed to incubate for 1 hour at 37°C/5% CO_2, after which they were removed and the wells washed three times with PBS. 100μl of C2C12 cells (ECACC lot 91031101) were cultured in the wells at a cell density of 3.4 x 10^4 cells ml^{-1} (100μl per well in a 96 well plate, hence 1.06 x10^4 cells/cm^2) and incubated at 37°C/5% CO_2 in a humidified atmosphere for approximately 4 days.

After 4 days, the cells were lysed using the freeze thaw method, alkaline phosphatase activity was assessed using the pNPP assay and normalised to DNA levels using the PicoGreen assay outlined in the general methods section.

The results are as seen in tables (1.3a to 1.3d) and as shown in Figures (1.3a to 1.3d).

As can be seen from these results the increase in alkaline phosphatase expressed by cultures grown in conditions of Follistatin and BMP, compared to those cultures grown in BMP alone, indicates that these cells have been stimulated to differentiate further along an osteoblastic lineage.

This result therefore suggests that cells respond to Follistatin and BMP resulting in a higher level of osteogenic tissue regeneration.

Example 1.4: The effect of Follistatin and BMP-4 on C2C12 cells- Solution

BMP-4 was prepared by diluting the contents of an ampoule with 1ml of SFDMEM to give a concentration of 10μgml^{-1}. This was further diluted to 2.5μgml^{-1} with SFDMEM. Follistatin was prepared by diluting the contents of an ampoule with 1ml of SFDMEM to give a final concentration of 25μgml^{-1}.

Four conditions were initially set up in wells of a 96 well plate (a minimum of four replicates for each condition):
Condition 1 - 20µl of Follistatin+80µl PBS
Condition 2 - 20µl of Follistatin+10µl BMP-4 + 70µl PBS
Condition 3 - 10µl BMP-4 + 90µl PBS
Condition 4 - 100µl PBS

The above solutions were incubated for 45 minutes at 37°C/5% CO_2 in a humidified atmosphere. Following incubation 100µl C2C12 cells (ECACC lot 91031101) at 3.4 x 10^4 cells/ml (100µl per well in a 96 well plate, hence 1.06 x10^4 cells/cm^2) were added, without removal of

the reagents. The plate was incubated at 37 °C /5% CO_2 for approximately 4 days.

The cells were lysed using the freeze thaw method, alkaline phosphatase activity of the cultures was assessed using the pNPP assay and and normalised to DNA levels using the PicoGreen assay outlined in the general methods section.

The results are as seen in table (1.4) and as shown in Figure (1.4).

As can be seen from these results the increase in alkaline phosphatase expressed by cultures grown in conditions of Follistatin and BMP, compared to those cultures grown in BMP alone, indicates that these cells have been stimulated to differentiate further along an osteoblastic lineage.

This result therefore suggests that cells respond to Follistatin and BMP resulting in a higher level of osteogenic tissue regeneration.

Example 1.5: The effect of Follistatin and BMP-4 on C2C12 cells- Bound

BMP-4 was prepared by diluting the contents of an ampoule with 1ml of SFDMEM to give a concentration of 10μgml^{-1}. This was further diluted to 2.5μgml^{-1} with SFDMEM. The follistatin was prepared by diluting the contents of an ampoule with 1ml of SFDMEM to give a final concentration of 25μgml^{-1}.

Four conditions were set up in wells of a 96 well plate (a minimum of four replicates for each condition):
Condition 1 – 20μl Follistatin + 80μl PBS
Condition 2 – 20μl Follistatin + 80μl PBS

Condition 3 – TCP
Condition 4 – TCP

The above solutions were added to the wells of a 96 well tissue culture plate and left to incubate overnight at 4°C. Following incubation, the protein solutions were removed and the wells washed three times with PBS. The wells were blocked with 200µl/well BSA (2mg ml^{-1}) for 1 hour, after which the blocking solution was removed and the wells washed three times with PBS.

100µl/well of BMP-2 (2.5µg ml^{-1}) was added to the wells in columns 2 and 3 (see list above) or 100µl/well of SFDMEM was added to the wells in column 1 and 4. These solutions were allowed to incubate for 1 hour at 37°C/5% CO_2, after which they were removed and the wells washed three times with PBS.

C2C12 myoblasts were added at a concentration of 3.4 $x10^4$ cells/ml (100µl per well in a 96 well plate, hence 1.06 $x10^4$ cells/cm^2). The plate was then incubated at 37 °C /5% CO_2 in a humidified atmosphere for approximately 4 days. After 4 days the cells were lysed using the freeze thaw method, alkaline phosphatase activity of the cultures was assessed using the pNPP assay and and normalised to DNA levels using the PicoGreen assay outlined in the general methods section.

The results are as seen in table (1.5) and as shown in Figure (1.5).

As can be seen from these results the increase in alkaline phosphatase expressed by cultures grown in conditions of Follistatin and BMP, compared to those cultures grown in BMP alone, indicates that these cells have been stimulated to differentiate further along an osteoblastic lineage.

This result therefore suggests that cells respond to Follistatin and BMP resulting in a higher level of osteogenic tissue regeneration.

Example 1.6: The effect of Follistatin and BMP-2 on MC3T3E1 cells – Solution

BMP-2 was prepared by diluting the contents of an ampoule with 1ml of SFDMEM to give a concentration of 10μgml^{-1}. This was further diluted to 1μg/ml with SFDMEM when required. The follistatin was prepared by diluting the contents of an ampoule with 1ml SFDMEM to give a final concentration of 25μgml^{-1}.

Four conditions were prepared in wells of a 96 well plate (a minimum of 4 replicates for each condition):
Column 1 - 20μl of Follistatin + 80μl PBS
Column 2 - 10μl of BMP-2 +20μl of Follistatin + 70μl PBS
Column 3 - 10μl of BMP-2 + 90μl PBS
Column 4 - 100μl of PBS

These protein mixtures were allowed to incubate for 45 minutes at room temperature, after which MC3T3E1 cells (DSMZ, lot. ACC210/3) were added without the removal of the reagents. Cells were cultured at a cell density of 6.4 x 10^4 cells ml^{-1} (100μl well^{-1}, i.e. 6.4 x 10^3 cells well^{-1} in 96 well plates, hence 2.0 x 10^4 cell cm^{-2}). The plate was incubated for approximately 4 days at 37°C, 5% CO_2 in a humidified atmosphere.

The cells were lysed using the freeze thaw method, alkaline phosphatase activity of the cultures was assessed using the pNPP assay and and normalised to DNA levels using the PicoGreen assay outlined in the general methods section.

The results are as seen in table (1.6).

As can be seen from these results the increase in alkaline phosphatase expressed by cultures grown in conditions of Follistatin and BMP, compared to those cultures grown in BMP alone, indicates that these cells have been stimulated to differentiate further along an osteoblastic lineage.

This result therefore suggests that cells respond to Follistatin and BMP resulting in a higher level of osteogenic tissue regeneration.

Example 1.7: The effect of Follistatin and BMP-2 on MC3T3E1 cells – Bound

BMP-2 was prepared by diluting the contents of an ampoule with 1ml of serum free SFDMEM to give a concentration of 10μgml^{-1}. This was further diluted to 1μg/ml with SFDMEM when required. The Follistatin was prepared by diluting the contents of an ampoule with 1ml SFDMEM to give a final concentration of 25μgml^{-1}. The BSA was diluted in PBS to give a final concentration of 2mgml^{-1}.

Five conditions were initially set up in wells of a 96 well plate (a minimum of four replicates for each condition):

Column 1) 50μl of follistatin

Column 2) 50μl of follistatin

Column 3) 50μl of BMP-2

Column 4) 50μl of BSA

Column 5) 50μl of BSA

The above solutions were added to the wells of a 96 well tissue culture plate and left to incubate overnight at 4°C. Following incubation, the protein solutions were removed and the wells washed three times with PBS. The wells were blocked with 200µl/well BSA (2mg ml^{-1}) for 1 hour, after which the blocking solution was removed and the wells washed three times with PBS.

100µl/well of BMP-2 (1µg ml^{-1}) was added to the wells in columns 2 and 5 (see list above) or 100µl/well of SFDMEM was added to the wells in column 1, 3 and 4. These solutions were allowed to incubate for 1 hour at 37°C/5% CO_2, after which they were removed and the wells washed three times with PBS. MC3T3E1 cells were cultured at a cell density of 6.4 x 10^4 cells ml^{-1} (100µl $well^{-1}$, i.e. 6.4 x 10^3 cells $well^{-1}$ in 96 well plates, hence 2.0 x 10^4 cell cm^{-2}). The plate was incubated for 4 days at 37°C, 5% CO_2 in a humidified atmosphere.

The cells were lysed using the freeze thaw method, alkaline phosphatase activity of the cultures was assessed using the pNPP assay and and normalised to DNA levels using the PicoGreen assay outlined in the general methods section.

The results are as seen in table (1.7) and as shown in Figure (1.7).

As can be seen from these results the increase in alkaline phosphatase expressed by cultures grown in conditions of Follistatin and BMP, compared to those cultures grown in BMP alone, indicates that these cells have been stimulated to differentiate further along an osteoblastic lineage.

This result therefore suggests that cells respond to Follistatin and BMP resulting in a higher level of osteogenic tissue regeneration.

Example 1.8: The effect of Follistatin-288 and BMP-2 on C2C12 cells – Solution

BMP-2 was prepared by diluting the contents of an ampoule with 1ml of serum free SFDMEM to give a final concentration of 10μgml^{-1}. The Follistatin-288 was prepared by diluting the contents of an ampoule with 1ml of SFDMEM to give a final concentration of 25μgml^{-1}.

Four conditions were initially set up in wells of 96 well plate (a minimum of four replicates for each condition):

Condition 1 - 20μl of Follistatin 288 + 80 μl PBS
Condition 2 - 20μl of Follistatin 288 + 10 μl BMP-2 + 70μl PBS
Condition 3 - 10μl BMP-2 + 90μl PBS
Condition 4 - 100μl BMP-2 + 70μl PBS

The above solutions were added to the wells of a 96 well tissue culture plate and left to incubate for 45 minutes at 37°C. Following incubation 100μl C2C12 myoblasts at 3.4 x 10^4 cells/ml were added, without removal of the reagents (100μl per well in a 96 well plate, hence 1.06 x 10^4 cells/cm^2). The plate was incubated at 37°C/5% CO_2 for approximately 3 days.

The cells were lysed using the freeze thaw method, alkaline phosphatase activity of the cultures was assessed using the pNPP assay and and normalised to DNA levels using the PicoGreen assay outlined in the general methods section.

The results are as seen in table (1.8) and as shown in Figure (1.8).

As can be seen from these results the increase in alkaline phosphatase expressed by cultures grown in conditions of Follistatin and BMP, compared to those cultures grown in BMP alone, indicates that these cells have been stimulated to differentiate further along an osteoblastic lineage.

This result therefore suggests that cells respond to Follistatin and BMP resulting in a higher level of osteogenic tissue regeneration.

Example 1.9: The effect of Follistatin-288 and BMP-2 on C2C12 cells – Bound

BMP-2 was prepared by diluting the contents of an ampoule with 1ml of serum free SFDMEM to give a concentration of 10μgml^{-1}. This was further diluted to 1μg/ml with SFDMEM when required. The Follistatin-288 was prepared by diluting the contents of an ampoule with 1ml SFDMEM to give a final concentration of 25μgml^{-1}. The BSA was diluted in PBS to give a final concentration of 2mgml^{-1}.

4 conditions were prepared in the wells of a 96 well plate (4 replicates for each condition):
Condition 1 – 20μl Follistatin 288 + 80μl PBS
Condition 2 – 20μl Follistatin 288 + 70μl PBS
Condition 3 – TCP
Condition 4 – TCP

The above solutions were incubated overnight at 4°C. Following incubation, the protein solutions were removed and the wells washed 3 times with PBS. The wells of the plate were blocked with BSA (2mgml^{-1} in PBS) at 200μl /well for 1 hour at room temperature. After this incubation the solutions were removed and the plate washed 3 times with PBS.

100µl/well of BMP-2 (1µgml^{-1}) added to conditions 2 and 3. 100µl SFDMEM was added to the wells of condition 1, those of condition 4 were left empty. These solutions were allowed to incubate for 1 hour at 37°C/5% CO_2 after which they were removed and the plate washed three times in PBS.

C2C12 cells were added at a concentration of 3.4 x 10^4 cells/ml (100µl per well in a 96 well plate, hence 1.06 x 10^4 cells/cm^2). The plate was then incubated for 4 days at 37°C/5% CO_2.

The cells were lysed using the freeze thaw method, alkaline phosphatase activity of the cultures was assessed using the pNPP assay and and normalised to DNA levels using the PicoGreen assay outlined in the general methods section.

The results are as seen in table 1.9 and as shown in Figure 1.9.

As can be seen from these results the increase in alkaline phosphatase expressed by cultures grown in conditions of Follistatin and BMP, compared to those cultures grown in BMP alone, indicates that these cells have been stimulated to differentiate further along an osteoblastic lineage.

This result therefore suggests that cells respond to Follistatin and BMP resulting in a higher level of osteogenic tissue regeneration.

Example 1.10: Intramuscular *In Vivo* Study

Young Adult Sprague Dawley rats of about 285-365g were anaesthetised and shaved on the rear limbs. Protein solutions (BMP-2 and Follistatin 300) and controls were loaded onto collagen

sponges (10mm x 3mm x 3mm, Duragen, Life Sciences) were implanted into the calf muscle. Eight groups were implanted (see list below):

Group 1	Carrier
Group 2	Carrier + BMP (A)
Group 3	Carrier + BMP (B)
Group 4	Carrier + FS300 (A)
Group 5	Carrier + FS300 (B)
Group 6	Carrier + FS300 (A) + BMP (A)
Group 7	Carrier + FS300 (B) + BMP (B)
Group 8	Carrier + FS300 (A) + BMP (B)

(A = 20μg of protein & B = 5μg of protein)

Treatment Day : Day 1

Animal	Left limb	Right limb
1	Carrier + FS300(B)	Carrier
2	Carrier + BMP2(A)	Carrier
3	Carrier + FS300(B) + BMP2(B)	Carrier + BMP2(B)
4	Carrier	Carrier + BMP2(B)
5	Carrier + FS300(A)	Carrier + FS300(A) + BMP2(A)
6	Carrier + FS300(A) + BMP2(B)	Carrier + FS300(B) + BMP2(B)
7	Carrier + BMP2(A)	Carrier + BMP2(B)

Treatment Day : Day 2

Animal	Left limb	Right limb
8	Carrier + FS300(B) + BMP2(B)	Carrier + FS300(B)
9	Carrier + FS300(A) + BMP2(A)	Carrier + FS300(B) + BMP2(B)
10	Carrier + FS300(A) + BMP2(B)	Carrier + FS300(A)
11	Carrier + FS300(A)	Carrier + BMP2(A)
12	Carrier + FS300(B)	Carrier + FS300(A) + BMP2(B)

13	Carrier + BMP2(A)	Carrier + FS300(A) + BMP2(B)
14	Carrier + FS300(A) + BMP2(A)	Carrier + BMP2(A)

Treatment Day : Day 3

Animal	Left limb	Right limb
15	Carrier	Carrier + FS300(A)
16	Carrier	Carrier + FS300(A) + BMP2(A)
17	Carrier + FS300(A) + BMP2(A)	Carrier + BMP2(B)
18	Carrier	Carrier + FS300(A) + BMP2(B)
19	Carrier + FS300(B)	Carrier + FS300(A) + BMP2(A)
20	Carrier + BMP2(B)	Carrier + FS300(B)
21	Carrier + FS300(A) + BMP2(A)	Carrier + FS300(A) + BMP2(B)

Treatment Day : Day 4

Animal	Left limb	Right limb
22	Carrier + FS300(A)	Carrier + FS300(B)
23	Carrier	Carrier + FS300(B)+ BMP2(B)
24	Carrier + FS300(B)+ BMP2(B)	Carrier + FS300(A)
25	Carrier + BMP2(A)	Carrier + FS300(B)+ BMP2(B)
26	Carrier + BMP2(A)	Carrier + FS300(B)
27	Carrier + BMP2(B)	Carrier + FS300(A)
28	Carrier + BMP2(B)	Carrier + FS300(A)+ BMP2(B)

Radiographic Analysis

Radiological assessment was carried out between 17 and 18 days after implantation (See figure 1.10a and 1.10b). When scanned and measured at equivalent magnification, the calcified tissue in the rat treated with follistatin and BMP-2 at 5μg (Figure 1.10b) has an area of 7.77 mm^2 and the calcified tissue in the rat treated with BMP-2 alone at 5μg BMP-2 has an area of 3.0 mm^2 (Figure 1.10a), the 20μg BMP-2 alone control has an area of 4.62 mm^2 , (data not shown) therefore

i.e more bone formed with follistatin and BMP-2. No bone was observed in the negative controls (Carrier alone).

Histology

Animals were terminated at 4 weeks post implantation. The skin around the implantation site was removed over the calf muscle, and the calf muscle was excised. Samples were fixed in 10% buffered formalin overnight, processed for paraffin embedding, sectioned at 5 µm and stained with haematoxylin and eosin (H&E) and counterstained with van Gieson. From the photomicrographs (Figures 1.10c and 1.10d, where B is bone, stained dark red, O is osteoid stained pink and M is muscle stained yellow) it could be clearly seen that the material generated in the BMP-2 and follistatin groups was bone.

Further tests, incuding alkaline phosphastase activity and calcium content, show that the level of bone regeneration is greater in samples of Follistatin and BMP.

Example 1.11:

Follistatin purchased from R+D Systems UK was found to be adherent to a solid matrix carrier. The concentration of the follistatin used was approximately 25µg/ml.

The follistatin covered carrier was implanted subcutaneously into 28 to 35 day old male rats. Implants without follistatin served as controls.

The animals were sacrificed 21 days after implantation and the bone forming activity at the implantation site were quantitated.

Comparison of test runs for follistatin on the carrier in the presence of BMP-2 were made to 1/ carrier and BMP-2 and 2/ carrier and follistatin.

Animals with the follistatin covered solid matrix carrier in the presence of BMP-2 showed greater bone formation at the implantation site than controls.

Example 1.12

A bone conduction chamber implant consisting of a threaded titanium chamber with a cylindrical interior space is implanted into a bone of a rat. The interior of the chamber is 2mm in diameter and 7mm long. The outside diameter is 3.5mm and the overall length is 13mm.

One end of the chamber has holes for tissue ingrowth. For implanting the chamber in the bone, the chamber is screwed into the bone.

Male Sprague-Dawley rats were used (1 chamber per animal).

After implantation of the chamber the rats were randomly divided into groups. One group had a suitable matrix with follistatin implanted, the second group had matrix alone implanted and the third group had nothing implanted into the chamber.

The rats were sacrificed after 6 weeks of implantation of test materials. Sections were cut from the tissue in the chamber and bone ingrowth was assessed. The bone tissue treated with follistatin show improved bone regeneration over controls.

Example 1.13

Follistatin purchased from R+D Systems UK was found to be adherent to a solid matrix carrier. The concentration of the follistatin used was approximately 25µg/ml.

The follistatin covered carrier was implanted intramuscularly into 28 to 35 day old male rats. Implants without follistatin served as controls.

The animals were sacrificed 21 days after implantation and the bone forming activity at the implantation site were quantitated. Comparison of test runs for follistatin on the carrier in the presence of BMP-2 were made to 1/ carrier and BMP-2 and 2/ carrier and follistatin.

Animals with the follistatin covered solid matrix carrier in the presence of BMP-2 showed greater bone formation at the implantation site than controls.

Example 1.14

Follistatin purchased from R+D Systems UK was found to be adherent to a solid matrix carrier. The concentration of the follistatin used was approximately 25µg/ml.

The follistatin covered carrier was implanted into a partial wedge osteotomy of sheep fibula. Animals were sacrificed at 30 days after implantation and the bone forming activity at the implantation site were quantitated.

Animals with the follistatin covered solid matrix carrier showed greater bone formation at the implantation site than controls of carrier alone.

Example 1.15

Segmental defect *In vivo* Model

The segmental defect radius/ulna model is well documented in the published literature and has been used to study compounds such as demineralised bone matrix and bone morphogenic proteins. Radius/ulna models have been performed most commonly in the following species: rat, rabbit and dog. It has been reported that the more active nature of the dog than the rabbit or rat, can lead to fracture of the long bone supporting the defect. Accordingly, the rabbit New Zealand White rabbit (skeletally mature i.e. growth plates fused) was selected as the most appropriate species.

An X-ray is taken prior to any surgery under veterinary surgeon supervision to confirm a fused epiphyseal plate - and thus skeletal maturity. If the growth plate is fused anaesthesia will be maintained and the surgical procedure will be followed.

Surgical Procedure

The surgical site is prepared for aseptic surgery by shaving the fur and washing the skin with a suitable surgical scrub (e.g. Hibitane, Pevidine).

1. An incision is made directly over the ulna, which is then exposed by dissection of the surrounding muscles.
2. A distance of 3cm is measured distally from the point of the ulna and a positioning device is placed along the midshaft of the ulna. A scalpel is used to mark the ulna at either end of the device.

3. Using an oscillating saw a complete osteotomy of the ulna is performed inside each of the marks.
4. Using a scalpel, the interosseous ligament between the radius and ulna is cut to release the ulna segment.
5. The periosteum of the immediately adjacent segment of the radius is removed by scraping with a scalpel.
6. The defect site is irrigated with saline to remove debris.
7. Bone graft material is implanted in the defect or, alternatively the defect is left empty.
8. The surgical site is closed with sutures.

Sample preparation

Each implant contains either recombinant BMP-2, follistatin or combinations of these.

Analyses

The ulna and radius construct is isolated at the humero-ulna / humero-radial joint and the radiocarpal joint, whilst taking care not to exert excessive bending force on the radius and ulna. After removal of the skin, samples are placed in formalin.

Bone healing of the segmental defect is assessed by analysis of radiographs and histology.This shows increased bone growth with follistatin and BMP over controls

Example 2.1:

Experimental devices are produced by the manufacture of an appropriately sized scaffold, which following sterilisation is coated

with collagen IIa (either the entire protein, or the collagen IIa propeptide which contains the BMP binding site).

Osteochondral defects, 3mm in diameter and 3mm in depth are created on the patellar grooves of white New Zealand rabbits. The defects are either left empty, filled with the scaffold only, or filled with the device described above. Rabbits are sacrificed at 1, 3 and 6 months and the defects sites examined histologically.

Grading for cartilage repair is performed blind by experienced histologists, using the O'Driscoll scoring system. At all time points cartilage healing is significantly improved in defects treated with scaffolds coated with collagen IIa, than either of the control groups.

This data shows that collagen IIa is effective in the healing of osteochondral defects and it is believed that it has this effect through the binding and presentation of autologous BMPs.

Methods to Determine the Effect of Follistatin on Chondrogenesis in vitro

Example 2.2: Effect on Chondrocytes in Monolayer

Primary chondrocytes were isolated from freshly terminated ovine stifle joints. The articular cartilage was dissected from patellar groove and back of patella, the tissue chopped (approx: 1-4mm^3) and washed in 0.25% gentamicin solution. The gentamicin solution was removed and the chopped cartilage gently shaken in collagenase solution (0.2%) overnight at 37°C. Worthington's type II collagenase was used, diluted in culture media and sterile filtered. Culture media was standard DMEM (4.5g/l glucose) with 10% foetal calf serum, 1% penicillin/streptomycin, 1% non-essential amino acids and 1% L-

glutamine. This media was used throughout all the cell culture experiments unless otherwise stated.

Following overnight collagenase treatment the resulting digest was poured through a 70μm nylon cell strainer and the filtrate transferred into centrifuge tubes and washed with equal volume of PBS and culture media. It was spun at 1000rpm for 10 minutes. The media was removed and the pellet washed in culture media before re-spinning at 1000rpm for 5 minutes. The cell pellet was resuspended in appropriate volume (minimum of 5ml) of culture media and a small aliquot taken to perform cell count.

The chondrocytes were seeded into wells of a 24-well plate at a density of 1×10^5 per well. BMP-2 (supplied by R&D systems) was applied at a concentration of between 50ng and 1000ng per ml. Follistatin (also supplied by R&D systems) was applied at a similar concentration, though the ratios of the two factors were varied. Ascorbic acid was added to the media at a concentration of 50ng/ml. Appropriate controls were set, i.e. BMP alone, follistatin alone and no growth factor treatment. The cells were incubated at 37°C, 5% CO_2, for between 4 days and one month. The cells were fed with media supplemented as appropriate every 2-3 days. At the end of the duration the samples were analysed by biochemical analysis:

Biochemical analysis: The media was retained when feeding the cells, or upon termination, for GAG analysis. The cell monolayers underwent papain digestion. Papain buffer was prepared by mixing 1.42g Sodium Phosphate, dibasic; 0.0788g Cysteine Hydrochloride and 0.1861g Ethylenediamine tetraacetic acid (EDTA). 90ml of UHQ water was added and stirred until dissolved, and the pH adjusted to 6.5. Papain solution was prepared by dissolving 0.0264g of papain in 25ml of papain buffer. 0.5ml of this solution was added to each of the

wells and a titre top placed on each plate. The plates were incubated at 60°C overnight in a hybridisation oven.

GAG Assay: The GAG assay was then performed on the cell digests. 1,9 Dimethylmethylene Blue (DMB) Solution was prepared by mixing 16mg 1,9-dimethylmethylene blue; 2g sodium formate; 5ml 100% ethanol and 2ml formic acid, dissolved in UHQ water, and made up to a final volume of 1000ml.

A stock 1mg/ml solution of chondroitin-4-sulphate (Chondroitin sulphate A, bovine trachea) in UHQ water was prepared and diluted 1:10 with blank papain solution to 100µg/ml. A set of standard was prepared ranging from 0-75µg/ml.

20µl of the standard or sample was placed into the wells of a 96 well plate. 200µl of DMB solution was added and the plate was read immediately on a plate reader, with a dual wavelength of 540nm (measurement) and 595nm (reference).

The GAG assay was also performed on the samples of media, however the standards were made up in 10% DMEM rather than blank papain solution.

DNA Assay: the Hoechst DNA assay was also performed on the cell digests. Hoechst dilution buffer was prepared by adding 1.211g Tris, 3.802g EDTA and 5.844g of NaCl to 800ml of UHQ grade water and stirring until dissolved. The pH was adjusted to pH 7.0 and made up to a final volume of 1000 ml with UHQ grade water. A 1mg/ml stock solution of Hoechst was diluted 1:2000 in the dilution buffer. DNA standards were made up from a stock solution of 1mg/ml salmon testis DNA, diluted to give a range of standards from 0-100µg/ml.

75µl of the standard or cell digest was put in a cuvette (4 clear sides). 1.5ml of the Hoechst solution was added, followed by a further 1ml of the dilution buffer. The samples were mixed and incubated for approximately 5 minutes, before being read on a fluorimeter at an excitation wavelength of 355nm and an emission wavelength of 460nm.

Collagen Assay: The hydroxyproline assay was used to determine the total amount of collagen in the samples. Collagen is composed of 14.3% hydroxyproline, and therefore by calculating the amount of hydroxyproline present than total collagen can be calculated. The purpose of these experiments was to make a direct comparison between samples and it is therefore not necessary to convert the hydroxyproline value to total collagen. Hydroxyproline assay stock solution was prepared by mixing 50g citric acid and 120g sodium acetate, dissolved in 650ml of UHQ water. A second solution of 34g of sodium hydroxide in 250ml of UHQ water was prepared and added to the initial solution. 12ml glacial acetic acid was added and made up to a volume of 1000ml with UHQ water. 10 drops of toluene was added. The hydroxyproline assay working solution was prepared by adding 150ml of isopropanol to 500ml of hydroxyproline stock solution. The solution was mixed well and adjusted to pH6.0 using hydrochloric acid, then made up to a final volume of 750ml with UHQ water.

Chloramine T Solution was prepared by adding 20ml hydroxyproline working solution to 2.5ml isopropanol and 0.3525g chloramine T. The mixture was stirred until the entire solid went into solution and stored in a glass container at room temperature. p-Dimethylaminobenzaldehyde (p-DAB) solution was prepared by adding 3.75g of p-DAB to 15ml of isopropanol and 6.5ml of perchloric acid.

The assay itself was performed as follows. 250µl of papain digest was added to 250µl of concentrated hydrochloric acid in a Pyrex (Corning) screw cap 13 ml glass tube and incubated overnight at 120°C on a heated block. The following day the contents were transferred to small glass vials and incubated uncapped at 90°C until dry. The samples were cooled to room temperature and the residue dissolved in 1ml of 0.25M sodium phosphate buffer. Hydrolysed papain solution (HPS) gave a representative blank for controls as well as a diluent for samples and standards.

Standards were prepared from a 1mg/ml stock solution of hydroxyproline, at a range of 0-30µg/ml. 50µl of standard or sample was added to the wells of a 96 well plate. 50µl of chloramine-T solution was added and the plate incubated at room temperature for 20 minutes. 50µl of p-DAB solution was added and the plate incubated at 60°C for 30 minutes. The plate was allowed to cool before being read on a plate reader at a single wavelength of 540nm.

Results: Table 2.2 shows the raw data for these results.

Figures 2.2a, 2.2b and 2.2c show GAG production, collagen production and proliferation respectively.

These results show that follistatin in combination with BMP-2 stimulates proliferation. The increase in the cell number corresponds with an increase in GAG and collagen production, both markers of cartilage production. In these experiments the extra-cellular matrix components expressed per µg DNA did not increase in the presence of follistatin. This suggests that in some situations the increase in collagen and GAG is due to an increase in the number of cells producing these molecules. These results are particularly significant

because an increase in proliferation is usually associated with a decrease in differentiation, i.e. GAG and collagen production. The follistatin-stimulated proliferation did not result in a decrease in differentiation indicating that follistatin is a suitable molecule for stimulating cartilage repair.

Example 2.3: Effect on Chondrocytes in Monolayer in the absence of ascorbic acid

A second experiment repeated the work above but investigated the effect without ascorbic acid. In this experiment the GAG production per cell had increased. Proliferation was not enhanced in the presence of follistatin, indicating that in the absence of ascorbic acid the follistatin is stimulating differentiation alone. Follistatin alone was also included in this experiment. It can be seen from the graph Fig. 2.3a that the follistatin alone had no stimulatory effect above the level of the control and therefore it is a combination of the BMP-2 and follistatin that is having the effect. GAG production per ug DNA is statistically enhanced in the BMP+ Follistatin samples over the BMP alone ($p=0.02$). Obviously no collagen was produced without ascorbate and there is therefore no data for this measurable. The data from this experiment is contained in table 2.3. The graph is figure 2.3a.

Figure 2.3b shows the effect of follistatin on cell morphology. Those cells treated with follistatin plus BMP-2 have a distinctly rounded morphology, indicating that they are retaining the chondrocytic phenotype, which is not seen in the other cells. Thus the cells treated with follistatin plus BMP-2 are retaining cartilage cell type characteristics.

Example 2.4: Effect of follistatin and BMP-7 (OP-1)

Example 2.2 was repeated, but growth factor BMP-7, or osteogenic protein-1, was used instead of BMP-2. The growth factor was supplied by R&D systems and used at the concentration described for BMP-2.The results of this experiment are contained in table 2.4. The results are expressed graphically in figure 2.4. As with BMP-2, the effect of OP-1 on GAG production by chondrocytes is enhanced in the presence of follistatin. The effect is significant, (p=0.093)

Example 2.5 : Effect of follistatin on Bone Marrow Stromal Cells

Example 2.2 is repeated using bone marrow stromal cells (BMSCs). The cells are isolated from the tibia of freshly terminated sheep. The flesh is stripped from the bone and the bone sawn open with a sterile hacksaw. The bone marrow is scooped out of the bone cavity using a sterile spatula and transferred to a falcon tube. Media is added to the tube, and it is spun at 1000rpm for 10 minutes. Any layer of fat accumulated on the surface of the media, is removed. The cells are resuspended and re-spun. Again the fat is removed and the cells resuspended. A cell count is performed and the cells transferred to a tissue culture flask at a density of $2x10^6$ per $175cm^2$. The BMSCs are allowed to settle for 2 days. Blood cells also present in bone marrow do not adhere to the tissue culture plastic and could therefore be separated from the BMSCs. Upon reaching confluence the cells are trypsinised from the surface of the flask, counted and plated into 24 well plates at a density of $5x10^4$. They are treated as described for chondrocytes, and analysis performed in an identical manner.

In the absence of BMP the BMSCs do not express any collagen or GAG. Relatively small levels are produced in the presence of BMP.

This is increased with follistatin, again indicating that follistatin can enhance BMP activity and stimulate chondrogenesis.

Example 2.6: Immunohistochemistry on cell monolayers

The presence of collagen type II, aggrecan and collagen I are assessed by immunocytochemical methods in order to determine if the chondrocytes were maintaining their differentiated phenotype in culture.

Chondrocytes are isolated as described in example 1 and grown on 12-well glass multitest slides. Growth factor treatment is the same as has already been described. After a one week culture period the slides are fixed in a 1:1 mixture of methanol: acetone and air-dried.

Immunohistochemistry is performed using an indirect streptavidin ABC immunoperoxidase method (Dako, Ely, UK). Tris buffered saline (TBS) is used throughout as diluent and wash buffer (0.15M NaCl, 0.05M Tris-(hydroxymethyl) aminomethane pH 7.6, in DDW) and all incubations are at ambient temperature.
Non-specific background staining is eliminated by blocking with 10% rabbit serum and endogenous avidin binding sites are blocked by treating sections with an avidin/biotin blocking kit (Vector Labs). Sections are incubated sequentially in primary antibody for 1 hour, biotinylated rabbit anti-Ig antibodies (F $(ab')_2$ fragments) for 30 minutes and streptavidin/HRP ABC complex (Vectastain elite ABC Kit, Vector Labs.) for 30 minutes, with washing between each step. Bound antibody is visualised by a 3,3'-diaminobenzidene substrate (DAB) reaction catalysed by H_2O_2. Sections are counter-stained with haematoxylin, before being dehydrated, cleared and mounted. Omission of primary antibody from the labelling protocol served as a

negative control. Staining for cell II and aggrecan is increased in BMP-2 and follistatin treated samples.

Example 2.7: Pellet Cultures

Pellet cultures are set up using chondrocytes and BMSCs, in media containing the following components: DMEM (4.5g/l glucose) + pyruvate; ITS+ premix (1ml per 100ml media); ascorbate-2 phosphate (100μM); dexamethasone (10-7M); HEPES (20μl/ml). The media is also supplemented with BMP-2 at concentrations ranging from 50-1000ng/ml, and follistatin at the same range. Controls of BMP-2 alone, and follistatin alone, and no growth factors are also set up. Aliquots of 500,000 cells (both chondrocytes and BMSCs) in 0.5ml media are placed into sterile 2ml round bottomed microcentrifuge tubes and centrifuged at 2500rpm for 10 minutes. This results in the cells forming into a pellet at the base of the tube. The pellet cultures are incubated at 37°C, 5% CO2, for two weeks. During this period the media was changed every 3-4 days.

At the end of the two-week period the pellet cultures are harvested and analysed. Analysis is performed either through total biochemical analysis or immunohistochemical and histological staining.

Biochemical Analysis: The biochemical analysis is performed on these samples as described in example. Prior papain digestion the samples undergo freeze-drying. Frozen samples are placed in vented tubes and are freeze dried overnight. Digestion was then performed overnight, in tightly sealed eppendorf tubes. Biochemical analysis is then performed on the digests.

Immunohistochemistry: the pellet cultures are fixed in 10% neutral buffered formalin followed by paraffin wax embedding. Prior to

immunolabelling, tissue sections (5μm) are dewaxed and rehydrated through graded alcohols to water. Immunohistological staining is performed as described in example 1.

Histological analysis: Sections treated as for the immunohistochemical analysis also undergo traditional histological staining. Histochemical staining for glycosaminoglycan (GAG) is carried out using the alcian blue staining method. Sections are rinsed in 3% acetic acid and placed in alcian blue solution (1% alcian blue (w/v) in 3% glacial acetic acid) at 60°C for 10 minutes. Slides are counterstained with 0.5% aqueous neutral red, rinsed with absolute ethanol, cleared in xylene and mounted. GAGs are stained blue using this technique. H&E staining is also performed, to examine the architecture of the tissue. The Safarin O staining method is used to identify cartilage in the samples.

Results show evidence of increased cartilage production in the follistatin plus BMP-2 treated samples.

Example 2.8: Three dimensional felt cultures

To determine the effect of follistatin on cells in a three-dimensional matrix, cultures on polyglycolic acid (PGA) felts are set up. The PGA felts are manufactured at S&N, Sterilisation is by ethylene oxide treatment. Cells (both chondrocytes and BMSCs) are seeded onto felts in 24 well plates that had been pre-wetted with FCS. One million cells in 100μl of standard 10% FCS DMEM and ascorbate are seeded onto each scaffold. After one hour the scaffolds are flooded with media containing the growth factor combinations already described. The scaffolds are cultured at 37°C, 5% CO_2 on an orbital shaker for two weeks, and were fed every 3-4 days.

Upon completion of the culture period the samples are harvested and submitted for biochemical, immunohistochemical and histological analysis, which is performed as has already been described.

Results show evidence of increased cartilage production in the follistatin plus BMP treated samples.

Example 2.9: Testing of GDF-5 in vitro

All of the experiments described to date are repeated using GDF-5 (CDMP-1). The growth factor was supplied by R&D systems and used at the concentration described for BMP-2. In all of the experiments described the trends detected with BMP-2 are repeated with GDF-5.

Results show evidence of increased cartilage production in the follistatin plus BMP treated samples.

Example 2.10: Rabbit in vivo study

The animal study is performed on 30 New Zealand White Rabbits. The rabbits are all male, and are approximately 8 months old, i.e. they have reached skeletal maturity
Bilateral, full thickness defects, 3mm in diameter and 3mm deep, are drilled into the trochlear groove of the femur in both hind joints. Defects are created with the joint at 90° and are placed in the centre of the groove.

The animals are divided into 4 treatment groups:

- Empty defect

- Scaffold only
- 30μg Follistatin
- 30μg Follistatin + 10μg BMP-2

The scaffolds are composed of PGA felt, 3.5 mm in diameter and 3mm deep so that they can be press fitted into the defects that have been created. A solution of the BMP-2 and follistatin or follistatin alone in PBS is injected onto the felts. A total of 30μl is injected per felt. For the scaffold only defect, 30μl PBS is injected.

A total of thirty animals have defects assigned according to the table, and evaluated at two time points of 3 and 6 months

Defect 1	Defect 2	3 months	6 months
Scaffold only	Untreated defect	N=2	N=3
Scaffold only	Active scaffold 1	N=2	N=3
Scaffold only	Active Scaffold 2	N=2	N=3
Active Scaffold 1	Untreated defect	N=2	N=3
Active Scaffold 1	Active Scaffold 2	N=2	N=3
Active Scaffold 2	Untreated Defect	N=2	N=3

Analysis

At the end of the study period the animal are anathetised and then terminated using a lethal does of anaesthetic. The hind limbs of the animals are removed and the treated area identified. Macroscopic examination is made of the defect site and the observations recorded

and photographed. The defect sites with the surrounding cartilage in tact are removed and transferred immediately to histological fixation. The samples are analysed histologically and immunohistochemically as described for the in vitro samples.

Untreated defects are filled with an unorganised fibrous tissue. Immunohistochemistry reveals that the repair tissue is composed largely of type I collagen. The defects that contain the scaffold alone show better tissue organisation but are still high in type I collagen and there is poor integration between the implant and the native tissue. The follistatin and follistatin +BMP-2 treated defects both have high levels of type II collagen and GAGs at both time points. There is evidence of tissue integration at the defect margins and subchondral bone and the tissue is highly organised in nature. It can therefore be concluded that the incorporation of follistatin into the healing joint results in cartilage repair through enhancing BMP activity.

Table 1.1

	ALP nmol/ml (a)	DNA conc pg/ml (b)	No. of cells (b/7.7) (c)	ALP nmol/ml (a/c) (d)	Mean ALP pmol/ml per cell (mean of d)
Follistatin	-38.5093	128940	16745.45	-0.0023	
	-31.677	147080	19101.3	-0.00166	
	-29.8137	188780	24516.88	-0.00122	0
Follistatin + BMP-2	241.6149	127620	16574.03	0.014578	
	270.4969	115135	14952.6	0.01809	
	245.9627	223330	29003.9	0.00848	13.7
TCP	-44.0994	116910	15183.12	-0.0029	
	-40.9938	167840	21797.4	-0.00188	
	-40.6832	205720	26716.88	-0.00152	0
BMP-2	19.87578	87170	11320.78	0.001756	
	29.19255	103860	13488.31	0.002164	
	37.57764	193300	25103.9	0.001497	1.8
BSA	-38.5093	102430	13302.6	-0.00289	
	-36.9565	139390	18102.6	-0.00204	
	-33.2298	171140	22225.97	-0.0015	0
BSA + BMP-2	83.22981	120740	15680.52	0.005308	
	77.63975	102650	13331.17	0.005824	
	59.93789	220560	28644.16	0.002092	4.4

Table 1.2a - Effect of follistatin on BMP-2 in C2C12 cells (solution experiment)

Treatment	pNP released (nmol/ml)	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP-2s	209	3.250307038	64.30161752		
	214.6666667	3.422720831	62.71813485		
	215.5	3.338504622	64.54985821		
	215.6666667	3.148748229	68.49282668	65.01560931	2.456022384
FSs	0	1.977414131	0		
	0	2.25907956	0		
	0	2.196929617	0		
	0	2.049281328	0	0	0
BMP-2s	28.5	1.10534449	25.78381695		
	35	1.107011269	31.61666098		
	16.16666667	1.301140428	12.42499758		
	19.83333333	1.170558067	16.94348524	21.69224019	8.634573673
TCPs	0	1.497624671	0		
	0	1.599183481	0		
	0	1.455853971	0		
	0	1.473601458	0	0	0

Table 1.2b - Effect of follistatin on BMP-2 in C2C12 cells (solution experiment)

Treatment	pNP released (nmol/ml)	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP	179.5	2.307530873	77.78877507		
	217.6666667	2.633666239	82.64777952		
	212.5	2.663425332	79.78447806		
	190.6666667	2.66113098	71.64873434	77.967	4.6607
FS	0	1.697165801	0		
	0	1.664909913	0		
	0	1.364187867	0		
	0	1.565645455	0	0	0
BMP-2	14.33333333	0.966630677	14.82813827		
	21.16666667	1.109825224	19.07207207		
	28.16666667	1.100674809	25.59036186		
	20.83333333	1.08431743	19.21331591	19.676	4.4370
TCP	0	0.974829611	0		
	0	1.076584115	0		
	0	1.141311829	0		
	0	1.060233484	0	0	0

Table 1.2c - Effect of follistatin on BMP-5 in C2C12 cells (solution experiment)

Treatment	pNP released (ALP) nmol/ml	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP-5s	43.297	7.18	6.03022284		
	49.122	7.6	6.46342105		
	53.261	7.35	7.24639456		
	37.719	7.24	5.20980663	6.237	0.8501
FSs	0	5.91	0		
	0	5.38	0		
	0	4.42	0		
	0	4.89	0	0	0
BMP-5s	19.494	6.21	3.13913043		
	19.478	5.6	3.47821429		
	19.772	6.24	3.16858974		
	19.052	6.11	3.11816694	3.226	0.1694
TCPs	0	6.27	0		
	0	5.84	0		
	0	4.9	0		
	0	5.03	0	0	0

Table 1.2d – Effect of follistatin on BMP-6 activity in C2C12 cells (solution experiment)

Treatment	pNP released (ALP) nmol/ml	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP-6s	250.45	4.306332046	58.15854358		
	211.34	5.282303732	40.00905868		
	203.03	5.533758044	36.68935259		
	202.11	4.820900901	41.92369936	44.195	9.5568
FSs	0.12	5.817696268	0.020626721		
	0.34	6.096396396	0.055770652		
	0.33	6.327631918	0.052152212		
	0.68	5.053539254	0.134559161	0.066	0.0485
BMP-6s	155.24	5.475662806	28.35090573		
	159.03	6.15951094	25.81860826		
	157.95	5.658893179	27.91181862		
	163.04	5.022934363	32.45911418	28.635	2.7785
TCPs	0.12	5.849433719	0		
	-0.07	6.708764479	0		
	-0.29	6.599227799	0		
	-0.15	4.672754183	0	0	0

Table 1.2e – Effect of follistatin on BMP-7 activity in C2C12 cells (solution experiment)

Treatment	pNP released (nmol/ml)	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP-7s	85.05	4.284749035	19.8494706		
	95.65	3.777631918	25.32009526		
	81.74	4.613166023	17.7188507		
	80.96	6.076229086	13.32405327	19.053	4.9837
FSs	4.55	5.817696268	0.782096519		
	5.19	6.096396396	0.851322595		
	5.08	6.327631918	0.802827988		
	5.94	5.053539254	1.175413844	0.903	0.1840
BMP-7s	30.27	5.66978121	5.33883035		
	37.04	5.070990991	7.304292211		
	41.95	4.164388674	10.07350737		
	52.14	3.362458172	15.50651259	7.572	2.3787
TCPs	4.7	5.849433719	0.803496582		
	4.52	6.708764479	0.673745518		
	3.46	6.599227799	0.524303768		
	4.11	4.672754183	0.879566919	0.720	0.1559

Table 1.3a - Effect of follistatin on BMP-2 in C2C12 cells (bound experiment)

Treatment	pNP released (ALP) nmol/ml	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS + BMP-2	251.84	6.52	38.62576687		
	284.41	6.37	44.64835165		
	236.17	6.39	36.95931142		
	335.16	5.68	59.00704225	44.810	10.0243
FS	0	5.88	0		
	0	5.56	0		
	0	5.68	0		
	0	5.93	0	0	0
BMP-2	36.42	8.65	4.210404624		
	31.4	8.28	3.792270531		
	30.5	8.3	3.674698795		
	40.5	7.98	5.07518797	4.188	0.6345
TCP	0	6.83	0		
	0	6.9	0		
	0	6.58	0		
	0	5.55	0	0	0

Table 1.3b – Effect of follistatin on BMP-6 activity in C2C12 cells (bound experiment)

Treatment	pNP released (ALP) nmol/ml	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP-6b	101.64	4.377477477	23.21885162		
	87.31	5.005045045	17.44439844		
	94.68	5.020913771	18.85712528		
	108.71	5.012277992	21.68874116	20.302	2.6258
FSb	25.81	4.895032175	5.272692615		
	21.82	4.735508366	4.607741834		
	19.18	5.078288288	3.776863169		
	19.69	5.66047619	3.478505931	4.284	0.8141
BMP-6b	34.37	5.290888031	6.496073967		
	36.06	6.051544402	5.958809455		
	34.12	5.628095238	6.062441831		
	34.34	5.429009009	6.325279612	6.211	0.2449
TCPb	15.76	5.573204633	2.827816496		
	15.28	5.063153153	3.017882244		
	11.66	5.625855856	2.072573542		
	13.14	5.944761905	2.210349247	2.532	0.4612

Table 1.3c – Effect of follistatin on BMP-6 activity in C2C12 cells (bound experiment)

Treatment	pNP released (nmol/ml)	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP-6b	25.76	2.37	10.8692		
	33.16	1.28	25.90625		
	39.73	1.82	21.82967		
	48.9	1.63	30	22.151	8.2278
FSb	0	1.9	0		
	0	1.81	0		
	0	1.82	0		
	0	1.27	0	0	0
BMP-6b	0.37	1.66	0.222892		
	-0.28	1.11	-0.25225		
	0	1.01	0		
	0.05	0.92	0.054348	0.006	0.1967
TCPb	0	1.6	0		
	0	1.88	0		
	0	1.85	0		
	0	1.66	0	0	0

Table 1.3d – Effect of follistatin on BMP-7 activity in C2C12 cells (bound experiment)

Treatment	pNP released (nmol/ml)	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP-7b	34.17	4.313101673	7.922372944		
	39.15	4.124388674	9.492315854		
	30.07	5.063552124	5.938518903		
	32.08	4.12018018	7.786067258	7.785	1.4541
FSb	25.81	4.895032175	5.272692615		
	21.82	4.735508366	4.607741834		
	19.18	5.078288288	3.776863169		
	19.69	5.66047619	3.478505931	4.284	0.8141
BMP-7b	16.7	4.28993565	3.892832285		
	18.44	3.36957529	5.472499771		
	15.67	4.889485199	3.20483637		
	18.25	3.569189189	5.113206118	4.421	1.0556
TCPb	15.76	5.573204633	2.827816496		
	15.28	5.063153153	3.017882244		
	11.66	5.625855856	2.072573542		
	13.14	5.944761905	2.210349247	2.532	0.4612

Table 1.4 - Effect of follistatin on BMP-4 in C2C12 cells (solution experiment)

Treatment	pNP released (ALP) nmol/ml	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP-4s	82	4.7613	17.22219		
	102.1666667	4.8615	21.01546		
	85.16666667	4.2813	19.89271		
	89.83333333	5.0527	17.77927	18.977	1.7802
FSs	-2.666666667	6.3443	-0.42032		
	0.666666667	8.0583	0.08273		
	-4.833333333	7.0452	-0.68605		
	-4.833333333	6.6655	-0.72513	0	0
BMP-4s	24.66666667	4.6547	5.299303		
	25.33333333	5.0515	5.015012		
	41.16666667	4.6542	8.845058		
	20.33333333	4.669	4.354965	5.879	2.0168
TCPs	-2.166666667	5.4711	-0.39602		
	-4.666666667	5.6445	-0.82676		
	-5.166666667	5.7691	-0.89558		
	-4	5.5138	-0.72545	0	0

Table 1.5 - Effect of follistatin on BMP-4 in C2C12 cells (bound experiment)

Treatment	pNP released (ALP) nmol/ml	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP-4b	184.1666667	3.79	48.59279		
	178.1666667	3.5472	50.22741		
	196.8333333	3.4499	57.05479		
	105.5	3.5566	29.66316	46.385	11.7346
FSb	-2.666666667	5.5329	-0.48197		
	-3.833333333	6.0595	-0.63262		
	0.333333333	5.6301	0.059206		
	-4.333333333	5.6836	-0.76243	0	0
BMP-4b	53.16666667	3.8842	13.68793		
	71.16666667	4.1643	17.08971		
	69	3.7796	18.2559		
	37.33333333	4.2224	8.841733	14.469	4.2224
TCPb	-4.5	4.791	-0.93926		
	-4.666666667	5.7638	-0.80965		
	-4.5	4.5645	-0.98587		
	-4.5	4.6975	-0.95796	0	0

Table 1.6 – Effect of follistatin on BMP-2 activity in MC3T3E1 cells (solution experiment)

Treatment	pNP released (nmol/ml)	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP-2s	130.521	4.0698	32.07062		
	131.678	3.8437	34.25814		
	148.667	3.8895	38.22265		
	130.455	4.0879	31.91247	34.116	2.9396
FSs	0	3.2027	0		
	0	2.6139	0		
	0	2.5035	0		
	0	2.8622	0	0	0
BMP-2s	0	1.2724	0		
	0	0.5672	0		
	55.556	1.7679	31.42485		
	63.264	1.592	39.73869	17.791	20.8216
TCPs	0	3.6327	0		
	0	3.2233	0		
	0	3.2787	0		
	0	3.6762	0	0	0

Table 1.7 – Effect of follistatin on BMP-2 activity in MC3T3E1 cells (bound experiment)

Treatment	pNP released (nmol/ml)	DNA conc. ug/ml	pNP/DNA	Mean pNP (nmol/ml) per ug DNA	SD
FS+BMP-2b	66.97	4.503256487	14.87146		
	63.09	3.035459527	20.78433		
	54.45	4.914297529	11.07992	15.579	4.8907
FSb	0	2.939935904	0		
	0	2.541300527	0		
	0	3.800268789	0	0	0
BMP-2b	36.15	4.176573969	8.65542		
	33.32	3.93156208	8.475003		
	32.47	5.230641993	6.207651	7.779	1.3641
TCPb	0	3.482063476	0		
	0	3.448568179	0		
	0	4.643233743	0	0	0

Table 1.8 – Effect of follistatin 288 on BMP-2 activity in C2C12 cells (solution experiment)

Treatment	pNP released (nmol/ml)	Mean pNP (nmol/ml) per well	SD
FS288+BMP-2s	83		
	148.8333333		
	199.3333333		
	162.8333333	148.5	48.5793
FS288s	-3.5		
	-3		
	-3.5		
	-3.333333333	0	0
BMP-2s	5.666666667		
	13.5		
	13.33333333		
	0.5	8.25	6.3282
TCPs	-3.833333333		
	-3.666666667		
	-3.666666667		
	-3.333333333	0	0

Table 1.9 – Effect of follistatin 288 on BMP-2 activity in C2C12 cells (bound experiment)

Treatment	pNP released (nmol/ml)	DNA conc. ug/ml	pNP/DNA	Mean pNP (ug/ml) per ug DNA	SD
FS288+BMP-2b	31.25	4.232	7.384216		
	15.5	3.8651	4.010246		
	21.75	4.2676	5.096541		
	26.5	3.9742	6.668009	5.790	1.5232
FS288b	1	4.2372	0.236005		
	1	4.8237	0.20731		
	1.75	4.5518	0.384463		
	1.75	4.3356	0.403635	0.308	0.1005
BMP-2b	5.5	5.0876	1.08106		
	6.75	5.443	1.240125		
	4.25	5.1542	0.82457		
	5.75	4.6221	1.244023	1.097	0.1971
TCPb	0.75	5.1705	0.145054		
	1	5.817	0.17191		
	0.75	5.5955	0.134036		
	0.5	5.416	0.092319	0.136	0.0331

Young	well number	vol digest	DNA/ml	total DNA	GAG med 1/m	GAG/ml med 2/	GAG med 1	GAG med 2	total GAG in media	GAG/ml (digest)	total GAG in diges	total GAG	collagen/ml	total collagen
Control	1	0.5	12.899	6.4495	54.9	52.75	9.62	26.375	35.995	19.24	9.62	45.615	2.55	1.275
	2	0.5	11.938	5.969	44.2	41.31	9.225	20.655	29.88	18.45	9.225	39.105	2.34	1.17
	3	0.5	12.768	6.384	45.6	41.82	9.465	20.91	30.375	18.93	9.465	39.84	2.55	1.275
	4	0.5	12.784	6.392	42.32	39.82	9.45	19.91	29.36	18.9	9.45	38.81	2.65	1.325
	5	0.5	12.735	6.3675	43.62	47.57	9.73	23.785	33.515	19.46	9.73	43.245	2.51	1.255
				6.31								41.32		1.26
				0.19								2.93		0.06
BMP-2 500ng	6	0.5	22.527	11.2635	82.7	95.43	41.35	47.715	89.065	64.59	32.295	121.36	6.49	3.245
	7	0.5	22.328	11.164	71.47	71.63	35.735	35.815	71.55	56.34	28.17	99.72	5.93	2.965
	8	0.5	23.807	11.9035	83.74	85.56	41.87	42.78	84.65	66.79	33.395	118.045	6.91	3.455
	9	0.5	21.575	10.7875	72.23	73.7	36.115	36.85	72.965	56.37	28.185	101.15	5.88	2.94
	10	0.5	22.589	11.2945	71.77	72.01	35.885	36.005	71.89	61.42	30.71	102.6	6.14	3.07
				11.28								108.38		3.14
				0.40								10.28		0.22
BMP:FS 100:300	11	0.5	15.331	7.6655	64.64	65.08	32.32	32.54	64.86	23.7	11.85	76.71	2.95	1.475
	12	0.5	14.929	7.4645	57.69	51.64	28.845	25.82	54.665	24.16	12.08	66.745	3.24	1.62
	13	0.5	15.675	7.8375	66.81	58.47	33.405	29.235	62.64	22.55	11.275	73.915	2.97	1.485
	14	0.5	17.164	8.582	61.93	46.85	30.965	23.425	54.39	25.2	12.6	66.99	3.1	1.55
	15	0.5	14.273	7.1365	58.67	48.05	29.335	24.025	53.36	21.61	10.805	64.165	3	1.5
				7.74								69.71		1.53
				0.54								5.33		0.08
BMP:FS 500:1500	16	0.5	26.996	13.498	95.38	117.95	47.69	58.975	106.665	62.39	31.195	137.86	7.34	3.67
	17	0.5	26.609	13.3045	92.79	107.45	46.395	53.725	100.12	61.04	31.345	131.465	6.82	3.41
	18	0.5	28.309	14.1545	93.86	105.63	46.93	52.815	99.745	62.69	30.875	130.62	7.43	3.715
	19	0.5	29.078	14.539	93.59	100.9	46.795	50.45	97.245	61.75	26.365	123.61	7.61	3.805
	20	0.5	26.682	13.341	88.79	92.92	44.395	46.46	90.855	52.73	26.365	117.22	6.97	3.485
				13.77								128.16		3.62
				0.65								7.93		0.16

Table 2.2

	well number	vol digest	DNA/ml	total DNA	GAG/ml (media)	vol media	total GAG in media	GAG/ml (digest)	total GAG in digest	total GAG	GAG/ug DNA
Control	1	0.5	8.19	4.095	17.1	0.5	8.55	8.65	4.325	12.875	3.14
	2	0.5	9.27	4.635	20.1	0.5	10.05	9.12	4.56	14.61	3.15
	3	0.5	9.27	4.635	17.68	0.5	8.84	7.24	3.62	12.46	2.69
	4	0.5	9.2	4.6	16.8	0.5	8.4	7.88	3.94	12.34	2.68
				4.49			8.96	8.22	4.11	13.07	2.92
				0.26			0.75	0.83	0.42	1.05	0.27
BMP-2	5	0.5	9.28	4.64	28.79	0.5	14.395	13.36	6.68	21.075	4.54
	6	0.5	9.05	4.525	28.93	0.5	14.465	12.41	6.205	20.67	4.57
	7	0.5	10.15	5.075	29.91	0.5	14.955	13.58	6.79	21.745	4.28
	8	0.5	9.78	4.89	26.44	0.5	13.22	12.71	6.355	19.575	4.00
				4.78			14.26	13.02	6.51	20.77	4.35
				0.25			0.74	0.55	0.27	0.91	0.26
FS	9	0.5	8.8	4.4	17.55	0.5	8.775	7.21	3.605	12.38	2.81
	10	0.5	8.82	4.41	18.25	0.5	9.125	6.93	3.465	12.59	2.85
	11	0.5	8.95	4.475	17.52	0.5	8.76	6.65	3.325	12.085	2.70
	12	0.5	8.81	4.405	17.95	0.5	8.975	7.7	3.85	12.825	2.91
				4.42			8.91	7.12	3.56	12.47	2.82
				0.04			0.17	0.45	0.22	0.31	0.09
BMP-2 + FS	13	0.5	6.93	3.465	25.06	0.5	12.53	10.56	5.28	17.81	5.14
	14	0.5	8.8	4.4	25.98	0.5	12.99	13.94	6.97	19.96	4.54
	15	0.5	7.69	3.845	26.1	0.5	13.05	12.63	6.315	19.365	5.04
	16	0.5	7.53	3.765	23.4	0.5	11.7	14.18	7.09	18.79	4.99
				3.87			12.57	12.83	6.41	18.98	4.93
				0.39			0.62	1.66	0.83	0.92	0.27

Table 2.3

	well number	vol digest	DNA/ml	total DNA	GAG/ml (media)	vol media	total GAG in media	GAG/ml (digest)	total GAG in diges	total GAG	GAG/ug DNA
Control	1	0.5	0.88	0.44	35.23	1	35.23	16.57	8.285	43.515	98.90
	2	0.5	0.99	0.495	36.98	1	36.98	16.75	8.375	45.355	91.63
	3	0.5	1.07	0.535	35.85	1	35.85	15.87	7.935	43.785	81.84
	4	0.5	0.99	0.495	40.63	1	40.63	17.12	8.56	49.19	99.37
											92.93
											8.20
OP-1	13	0.5	1.31	0.655	66.24	1	66.24	38.85	19.425	85.665	130.79
	14	0.5	1.19	0.595	66.48	1	66.48	39.35	19.675	86.155	144.80
	15	0.5	1.15	0.575	64.75	1	64.75	38.56	19.28	84.03	146.14
	16	0.5	1.29	0.645	54.1	1	54.1	28.35	14.175	68.275	105.85
											131.89
											18.70
OP-1 + FS	17	0.5	1.07	0.535	66.93	1	66.93	36.08	18.04	84.97	158.82
	18	0.5	1.06	0.53	61.74	1	61.74	34.56	17.28	79.02	149.09
	19	0.5	1.05	0.525	61.61	1	61.61	33	16.5	78.11	148.78
	20	0.5	1.14	0.57	63.36	1	63.36	31.24	15.62	78.98	138.56
											148.81
											8.27

Table 2.4

CLAIMS

1. A pharmaceutical compositon comprising a BMP binding protein.

2. A pharmaceutical composition comprising a BMP binding protein to aid tissue regeneration.

3. A pharmaceutical composition as claimed in either of claims 1 or 2 in which the BMP binding protein is selected from the group consisting of:-

Follistatin,
ZFSTA2,
FSRP
FLIK,
Alpha-2-HS glycoprotein,
Collagen IIa,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Chordin,
Sog,
Crim,
Nell,
Connective Tissue Growth Factor (CTGF),
Dan,
Gremlin,
Cerberus,
Endoglin,

Twisted Gastulation Gene, or derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding proteins.

4. A pharmaceutical composition as claimed in any one of claims 1, 2 or 3 in which the BMP binding protein is selected from the group consisting of:-

Follistatin,
ZFSTA2,
FSRP,
FLIK,
Collagen Iia,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Endoglin,
Dan,
Gremlin,
Cerberus,
Chordin,
Sog,
Crim,
Nell, or derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding proteins.

5. A pharmaceutical composition as claimed in any one of the preceding claims in which the BMP binding protein is selected from the group: follistatin, a protein described in the amino acid sequence (1) listed, or derivatives, fragments and/or analogues thereof.

6. A pharmaceutical composition as claimed in any one of claims 1 to 4 in which the BMP binding protein is collagen IIa or derivatives, fragments and/or analogues thereof.

7. A pharmaceutical composition as claimed in claim 2 in which the tissue is bone.

8. A pharmaceutical composition as claimed in claim 2 in which the tissue is cartilage.

9. Use of a BMP binding protein in the manufacture of a medicament for the treatment of diseases or clinical conditions that may be alleviated by the promotion of tissue regeneration e.g. cartilage and/or bone tissue regeneration.

10. Use of a BMP binding protein as claimed in claim 9 in which the BMP binding protein is selected from the group:

Follistatin,
ZFSTA2,
FLIK,
FSRP,
Alpha-2-HS glycoprotein,
Collagen Iia,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Chordin,
Sog,
Crim,
Nell,
Connective Tissue Growth Factor (CTGF),
Dan,
Gremlin,
Cerberus,

Endoglin,

Twisted Gastulation Gene, or derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding proteins.

11. Use of a BMP binding protein as claimed in claim 9 in which the BMP binding protein is selected from the group:

Follistatin,
ZFSTA2,
FLIK,
FSRP,
Collagen Iia,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Endoglin,
Dan,
Gremlin,
Cerberus,
Chordin,
Sog,
Crim,

Nell or derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding proteins.

13. Use of a BMP binding protein in the manufacture of a medicament as claimed in any one of claims 9, 10 or 11 in which the tissue is bone.

14. Use of a BMP binding protein is the manufacture of a medicament as claimed in one of claims 9, 10 or 11 in which the tissue is cartilage.

15. A scaffold for promoting tissue generation in which the scaffold comprises a BMP binding protein.

16. A scaffold for promoting tissue generation as claimed in claim 15 in which the BMP binding protein is Collagen IIa.

17. A scaffold for promoting tissue generation as claimed in claim 15 in which the BMP binding protein is Follistatin.

17. A scaffold for promoting tissue generation as claimed in claim 15 in which the BMP binding protein is Collagen IIa.

18.

19. A scaffold for promoting tissue generation as claimed in claim 15 in which the BMP binding is selected from the group:

Follistatin,
ZFSTA2,
FLIK,
FSRP,
Alpha-2-HS glycoprotein,
Collagen Iia,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Chordin,
Sog,
Crim,
Nell,
Connective Tissue Growth Factor (CTGF),
Dan,
Gremlin,
Cerberus,

Endoglin,

Twisted Gastulation Gene, or derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding proteins.

20. A scaffold for promoting tissue generation as claimed in claim 15 in which the BMP binding protein is selected from the group:

Follistatin,
FLIK,
FSRP,
Collagen IIa,
Collagen IV,
Collagen V Alpha 1,
Collagen V Alpha 2,
Endoglin,
Dan,
Gremlin,
Cerberus,
Chordin,
Sog,
Crim,

Nell or derivatives, fragments and/or analogues thereof, of the before mentioned BMP binding proteins.

21. A scaffold for promoting tissue generation as claimed in claim 15 in which the BMP binding protein is Endoglin.

22. A scaffold as claimed in any one of claims 15 to 21, in which the tissue is bone.

23. A scaffold as claimed in any one of claims 15 to 21, in which the tissue is cartilage.

24. A device for promoting tissue regeneration in which the device comprises a medicament according to any one of claims 1 to 9.

25. A method of manufacturing a scaffold for promoting tissue generation comprising the step of: coating a scaffold with a BMP binding protein.


Alkaline Phosphatase Released Per Cell
pNP released pmol/cell
0
2
4
6
8
10
12
14
16
18
20
FS
FS+BMP
BMP
BSA
BSA+BMP
TCP

Figure 1.1

Figure 1.2a


Effect of follistatin on BMP-2 activity in C2C12 cells (solution experiment)
pNP released (nmol/ml) per ug DNA
0
10
20
30
40
50
60
70
80
FS+BMP-2
FS
BMP-2
TCP
Treatment

Figure 1.2b


Effect of follistatin on BMP-2 activity in C2C12 cells (solution experiment)
pNP released (nmol/ml) per ug DNA
0
10
20
30
40
50
60
70
80
90
FS+BMP-2s
FSs
BMP-2s
TCPs
Treatment

Figure 1.2c


Effect of follistatin on BMP-5 activity in C2C12 cells (solution experiment)
pNP released (nmol/ml) per ug DNA
0
1
2
3
4
5
6
7
8
FS+BMP-5s
FSs
BMP-5s
TCPs
Treatment

Figure 1.2d


Effect of follistatin on BMP-6 in C2C12 cells (solution)
pNP released (nmol/ml) per ug DNA
0
10
20
30
40
50
60
FS+BMP-6s
FSs
BMP-6s
TCPs
Treatment

Figure 1.2e


Effect of follistatin on BMP-7 in C2C12 cells (solution)
pNP released (nmol/ml) per ug DNA
0
5
10
15
20
25
30
FS+BMP-7s
FSs
BMP-7s
TCPs
Treatment

Figure 1.3a


Effect of follistatin on BMP-2 activity in C2C12 cells (bound experiment)
pNP released (nmol/ml) per ug DNA
0
10
20
30
40
50
60
FS + BMP-2
FS
BMP-2
TCP
Treatment

Figure 1.3b


Effect of follistatin on BMP-6 activity in C2C12 cells (bound)
pNP released (nmol/ml) per ug DNA
25
20
15
10
5
0
FS+BMP-6b
FSb
BMP-6b
TCPb
Treatment

Figure 1.3c



Figure 1.3c


Effect of follistatin on BMP-7 in C2C12 cells (bound)
pNP released (nmol/ml) per ug DNA
0
1
2
3
4
5
6
7
8
9
10
FS+BMP-7b
FSb
BMP-7b
TCPb
Treatment

Figure 1.3d

Figure 1.4


Effect of follistatin on BMP-4 activity in C2C12 cells (solution experiment)
pNP released (nmol/ml) per ug DNA
25
20
15
10
5
0
FS+BMP-4s
FSs
BMP-4s
TCPs
Treatment

Figure 1.5


Effect of follistatin on BMP-4 activity in C2C12 cells (bound experiment)
pNP released (nmol/ml) per ug DNA
0
10
20
30
40
50
60
70
FS+BMP-4b
FSb
BMP-4b
TCPb
Treatment


Effect of follistatin on BMP-2 activity in MC3T3E1 cells (bound experiment)
pNP released (nmol/ml) per ug DNA
25
20
15
10
5
0
FS+BMPb
FSb
BMP-2b
TCPb
Treatment

Figure 1.7

Figure 1.8


Effect of follistatin 288 on BMP-2 activity in C2C12 cells (solution experiment)
pNP released (nmol/ml) per well
250
200
150
100
50
0
FS288+BMP-2s
FS288s
BMP-2s
TCPs
Treatment

Figure 1.9


Effect of follistatin 288 on BMP-2 activity in C2C12 cells (bound experiment)
pNP released (nmol/ml) per ug DNA
0
1
2
3
4
5
6
7
8
FS288+BMP-2b
FS288b
BMP-2b
TCPb
Treatment



Figure 1.10b



Figure 1.10a



Follistatin + BMP-2, x100 mag

Figure 1.10d



Follistain + BMP-2, x50 mag

Figure 1.10c


Effect of BMP-2 in the presence and absence of follistatin on GAG production by chondrocytes
GAG (ug)
160
140
120
100
80
60
40
20
0
control
BMP-2
BMP-2: FS
Treatment group

Fig 2.2a


Effect of BMP-2 in the presence and absence of follistatin on collagen production by chondrocytes
Collagen (ug)
0
0.5
1
1.5
2
2.5
3
3.5
4
control
BMP-2
BMP-2: FS
Treatment group

Fig 2.2b


Effect of BMP-2 in the presence and absence of follistatin on chondrocyte proliferation
DNA (ug)
0
2
4
6
8
10
12
14
16
control
BMP-2
BMP-2: FS
Treatment group

Fig 2.2c


Effect of BMP-2 in the presence and absence of follistatin on GAG production by chondrocytes in vitro (without ascorbate treatment)
GAG per ug DNA
0
1
2
3
4
5
6
Control
FS
BMP-2
BMP-2 + FS
Treatment group

Fig 2.3a



Fig 2.3b


Effect of OP-1 on GAG production by chondrocytes, in the presence and absence of follistatin
GAG per ug DNA
180
160
140
120
100
80
60
40
20
0
Control
OP-1
OP-1 +FS
Treatment group

Figure 2.4

INTERNATIONAL SEARCH REPORT

In ational Application No
PCT/GB 02/02427

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K38/17 A61P19/02 A61P19/08 A61P19/10 A61F2/28
C07K14/47 //(A61K38/17,38:18)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P A61F C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BIOSIS, WPI Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 21335 A (DEROBERTIS EDWARD M ;LAVALLIE EDWARD R (US); GENETICS INST (US); R) 22 May 1998 (1998-05-22) page 3, line 38 -page 4, line 30 page 14, line 36 -page 18, line 9 example 8 ---	1-25
X	US 5 837 258 A (GROTENDORST GARY R) 17 November 1998 (1998-11-17) column 13, line 40 -column 18, line 42 examples claims --- -/--	1-25

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
30 September 2002	11/10/2002

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Didelon, F

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 02/02427

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 24821 A (UNIV CALIFORNIA) 12 April 2001 (2001-04-12) page 4, line 16 -page 5, line 22 page 32, line 30 -page 34, line 21 page 38, line 1 -page 40, line 23 claims 26-50; example 1	1-25
X	EP 0 950 415 A (ROCHE DIAGNOSTICS GMBH) 20 October 1999 (1999-10-20) the whole document	1-6, 8-11, 14-21, 23-25
X	US 4 816 437 A (NIMBERG RICHARD B ET AL) 28 March 1989 (1989-03-28) claims; examples	1-6, 8-11, 14-21, 23-25
X	WO 98 49296 A (ECONOMIDES ARIS N ;ROJAS EDUARDO A (US); STAHL NEIL E (US); REGENE) 5 November 1998 (1998-11-05) page 15, line 25 -page 16, line 32 claims 21-28	1-5,7,8, 15-25
X	WO 89 01945 A (SALK INST FOR BIOLOGICAL STUDI) 9 March 1989 (1989-03-09) page 17, line 25 -page 18, line 2 page 20, line 28 -page 21, line 34	1-5,7,8
A	FUNABA MASAYUKI ET AL: "Follistatin and activin in bone: Expression and localization during endochondral bone development." ENDOCRINOLOGY, vol. 137, no. 10, 1996, pages 4250-4259, XP002215099 ISSN: 0013-7227 the whole document	1-6, 8-11, 14-21, 23-25
P,X	US 6 355 788 B1 (CONKLIN DARRELL C ET AL) 12 March 2002 (2002-03-12) column 42, line 33 -column 43, line 6	1-6, 8-11, 14-21, 23-25

INTERNATIONAL SEARCH REPORT

ternational application No.
PCT/GB 02/02427

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: -
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1,2,7-9,13-15,22-25 relate to compounds to be used defined by reference to a desirable characteristic or property, namely "BMP binding proteins".
The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds cited in e.g., claim 3.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

nformation on patent family members

Int tional Application No
PCT/GB 02/02427

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9821335	A	22-05-1998	US	5846770 A	08-12-1998
			AU	4896097 A	03-06-1998
			WO	9821335 A1	22-05-1998
			US	5986056 A	16-11-1999
US 5837258	A	17-11-1998	US	5770209 A	23-06-1998
			US	5585270 A	17-12-1996
			US	5408040 A	18-04-1995
			AU	722919 B2	17-08-2000
			AU	5885596 A	18-12-1996
			AU	720268 B2	25-05-2000
			AU	5958296 A	18-12-1996
			BR	9608558 A	30-11-1999
			BR	9609521 A	15-06-1999
			CA	2222509 A1	05-12-1996
			CA	2222609 A1	05-12-1996
			CN	1195295 A	07-10-1998
			CN	1191491 A	26-08-1998
			EP	0831903 A1	01-04-1998
			EP	0831885 A1	01-04-1998
			JP	11507332 T	29-06-1999
			JP	11506449 T	08-06-1999
			US	6150101 A	21-11-2000
			US	6069006 A	30-05-2000
			US	6232064 B1	15-05-2001
			WO	9638172 A1	05-12-1996
			WO	9638168 A1	05-12-1996
			US	6190884 B1	20-02-2001
			US	6149916 A	21-11-2000
			US	5916756 A	29-06-1999
			US	5783187 A	21-07-1998
WO 0124821	A	12-04-2001	AU	7994300 A	10-05-2001
			WO	0124821 A1	12-04-2001
EP 0950415	A	20-10-1999	EP	0950414 A1	20-10-1999
			EP	0950415 A1	20-10-1999
			AU	2359099 A	21-10-1999
			BR	9903179 A	09-05-2000
			CN	1236645 A	01-12-1999
			JP	2000053579 A	22-02-2000
			TR	9900748 A2	21-10-1999
			ZA	9902570 A	08-10-1999
US 4816437	A	28-03-1989	NONE		
WO 9849296	A	05-11-1998	AU	726385 B2	02-11-2000
			AU	6873698 A	24-11-1998
			EP	0975752 A1	02-02-2000
			JP	2001526535 T	18-12-2001
			NZ	500577 A	23-02-2001
			WO	9849296 A1	05-11-1998
WO 8901945	A	09-03-1989	US	5041538 A	20-08-1991
			AT	113654 T	15-11-1994
			AU	2420088 A	31-03-1989
			AU	620346 B2	20-02-1992
			DE	3852033 D1	08-12-1994

INTERNATIONAL SEARCH REPORT

In itional Application No
PCT/GB 02/02427

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8901945 A		DE 3852033 T2	27-04-1995
		EP 0377659 A1	18-07-1990
		JP 2709113 B2	04-02-1998
		JP 4504105 T	23-07-1992
		WO 8901945 A1	09-03-1989
		US 5182375 A	26-01-1993
US 6355788 B1	12-03-2002	NONE	